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ABSTRACT 
Cardiovascular diseases (CVD) are major contributors to morbidity and mortality 
worldwide. Several interacting environmental, biochemical, and genetic risk factors 
can increase disease susceptibility. While some of the genes involved in the etiology 
of CVD are known, many are yet to be discovered. During the last few decades, 
scientists have searched for these genes with genome-wide linkage and association 
methods, and with more targeted candidate gene studies. 
This thesis investigates variation within the upstream transcription factor 1 (USF1) 
gene locus in relation to CVD risk factors, atherosclerosis, and incidence and 
prevalence of CVD. This candidate gene was first identified in Finnish families 
ascertained for familial combined hyperlipidemia, a common dyslipidemia 
predisposing to coronary heart disease. The gene is a ubiquitously expressed 
transcription factor regulating expression of several genes from lipid and glucose 
metabolism, inflammation, and endothelial function. 
First, we examined association between USF1 variants and several CVD risk 
factors, such as lipid phenotypes, body composition measures, and metabolic 
syndrome, in two prospective population cohorts. Our data suggested that USF1 
contributes to these CVD risk factors at the population level. Notably, the 
associations with quantitative measurements were mostly detected among study 
subjects with CVD or metabolic syndrome, suggesting complex interactions 
between USF1 effects and the pathophysiological state of an individual.  
Second, we investigated how variation at the USF1 locus contributes to 
atherosclerotic lesions of the coronary arteries and abdominal aorta. For this, we 
used two study samples of middle-aged men with detailed measurements of 
atherosclerosis obtained in autopsy. USF1 variation significantly associated with 
areas of several types of lesions, especially with calcification of the arteries.  
Next, we tested what effect the USF1 risk variants have on sudden cardiac death and 
incidence of CVD. The atherosclerosis-associated risk variant increased the risk of 
sudden cardiac death of the same study subjects. Furthermore, USF1 alleles 
  
associated with incidence of CVD in the Finnish population follow-up cohorts. 
These associations were especially prominent among women, suggesting a 
sex-specific effect, which has also been detected in subsequent studies. 
Finally, as some of the low-yield DNA samples of the Finnish follow-up study cohort 
needed to be whole-genome amplified (WGA) prior to genotyping, we evaluated 
whether the produced WGA genotypes were of good quality. Although the samples 
giving genotype discrepancies could not be detected before genotyping with standard 
laboratory quality control methods, our results suggested that enhanced quality control 
at the time of the genotyping could identify such samples. In addition, combining two 
WGA reactions into one pooled DNA sample for genotyping markedly reduced the 
number of discrepancies and samples showing them. 
In conclusion, USF1 seems to have a role in the etiology of CVD. Additional studies 
are warranted to identify functional variants and to study interactions between USF1 
and other genetic or environmental factors. This USF1 study, and other studies with 
low DNA yield of some samples, can benefit from whole genome amplification of 
the low-yield samples prior to genotyping. Careful quality control procedures are, 
however, needed in WGA genotyping.  
 
Keywords: USF1, cardiovascular disease, atherosclerosis, genetic association 
analysis, follow-up study, lipid metabolism, familial combined hyperlipidemia, 
metabolic syndrome, cardiovascular risk factors, whole genome amplification 
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TIIVISTELMÄ 
Sydän- ja verisuonitaudeilla (SVT) on vakavia sosiaalisia ja terveydenhuollollisia 
vaikutuksia eri yhteiskunnissa. Yleisiä sairastumisen riskiä lisääviä tekijöitä 
tunnetaan useita ja ne voivat olla ympäristöllisiä, perinnöllisiä tai osittain molempia. 
Vaikka useita verenkiertoelinten sairauksiin vaikuttavia perinnöllisiä tekijöitä on jo 
tunnistettu, monia sairastumiseen vaikuttavia geenialueita on vielä tunnistamatta. 
Näitä alueita tutkijat ovat viime vuosikymmenten aikana etsineet koko perimän 
laajuisilla kytkentä- ja assosiaatioanalyyseillä, sekä tarkemmin kohdennetuilla 
ehdokasgeenianalyyseillä.  
Tässä väitöskirjatyössä analysoitiin upstream transcription factor 1 (USF1) -geeniä, 
tutkien sen yhteyttä SVT riskitekijöihin, ateroskleroosiin, sekä SVT:n 
ilmaantumiseen ja esiintymiseen. Tämä geeni tunnistettiin alun perin suomalaisissa 
perheissä, jotka valittiin familiaalisen kombinoidun hyperlipidemian (FKH) 
tutkimusta varten. USF1 säätelee rasva- ja sokeriaineenvaihduntaan, tulehdus-
reaktioihin ja endoteelin toimintaan liittyvien geenien ilmentymistä, mikä tekee siitä 
mielenkiintoisen ehdokasgeenin sydän- ja verisuonitaudeille. 
Tutkimme ensin miten perinnöllinen vaihtelu USF1:n alueella on yhteydessä perinteisiin 
SVT:n riskitekijöihin, kuten rasva-arvoihin, lihavuusmuuttujiin, sekä metaboliseen 
syndroomaan. Vaihtelu USF1:n alueella liittyi näihin riskitekijöihin kahdessa 
väestöpohjaisessa seurantaotoksessa. Lähes kaikki yhteydet havaittiin tarkastelemalla 
seuranta-otosten erityisryhmiä, kuten sydänsairaita, tai metabolista syndroomaa 
sairastavia. Tämä viittaisi monimutkaisiin yhdysvaikutuksiin USF1:n toiminnassa.  
Seuraavaksi tarkastelimme USF1:n vaikutusta ateroskleroosin muodostumiseen 
suonitasolla. Käytössämme oli kaksi äkkikuolleista miehistä koostuvaa suomalaista 
ruumiinavausaineistoa. Aineisto sisälsi tietoa erityyppisistä ateroskleroosimuuttujista 
ja havaitsimme USF1:n yhdistyvän varsinkin verisuonten kalkkeutumiseen. 
Tutkimme vielä USF1:n vaikutusta sydänperäisen äkkikuoleman riskiin sekä sydän- 
ja verisuonitaudin ilmaantumiseen. Havaitsimme ateroskleroosiin liittyvän 
riskialleelin kasvattavan myös sydänperäisen äkkikuoleman riskiä samassa 
tutkimusaineistossa. Lisäksi USF1:n eri muodot vaikuttivat SVT:n riskiin 
suomalaisissa seurantaotoksissa. Seurantaotoksissa riskivaikutus ilmeni pääasiassa 
  
naisilla, mikä viittasi sukupuolille ominaiseen geenivaikutukseen, jota on 
jälkeenpäin ehdotettu myös muissa tutkimuksissa.  
Testasimme myös miten koko perimän laajuinen DNA:n monistus (WGA) vaikuttaa 
genotyypityksen luotettavuuteen. Tarkoituksena oli tarkastella niitä suomalaisen 
väestöotoksemme näytteitä, joiden DNA saanto oli niin vähäistä, että niiden 
monistaminen ennen genotyypitystä oli tarkoituksenmukaista. Osa WGA-näytteistä 
antoi genotyypityksessä ristiriitaisia tuloksia, eikä näitä näytteitä voitu havaita 
muiden näytteiden joukosta normaaleissa näytteiden laaduntarkkailuissa ennen 
genotyypitystä. Genotyypitystulosten tarkasteluissa useat ristiriitaiset näytteet 
erottuivat kuitenkin muista hyvin. Lisäksi kahden erillisen WGA-reaktion 
yhdistäminen yhdeksi genotyypitettäväksi näytteeksi paransi genotyypityksen 
luotettavuutta huomattavasti. 
Tässä väitöskirjatyössä saimme siis viitteitä USF1-geenin roolista verenkiertoelinten 
sairauksissa. Tulevat USF1-tutkimukset sisältänevät selvitystyötä geenialueen 
toiminnallisista varianteista, sekä tutkivat tarkemmin geenin yhdysvaikutuksia 
sukupuolen, sekä muiden ympäristöllisten ja perinnöllisten tekijöiden kanssa. Tässä 
USF1-tutkimuksessa, kuten myös muissa vähäsaantoista DNA:ta sisältävissä 
tutkimuksissa, voidaan hyödyntää näytteiden koko perimän DNA:n monistusta 
ennen genotyypitystä. WGA-näytteiden genotyypitys vaatii kuitenkin huolellisen 
laaduntarkkailun, jotta genotyypitysvirheitä tuottavat näytteet tunnistetaan ennen 
tilastollisia analyysejä. 
 
Avansanat: USF1, sydän- ja verisuonitaudit, ateroskleroosi, geneettinen assosiaa-
tiotutkimus, seurantatutkimus, rasva-aineenvaihdunta, familiaalinen kombinoitu 
hyperlipidemia, metabolinen syndrooma, sydäntaudin riskitekijät, koko perimän 
DNA:n monistus 
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ABBREVIATIONS 
APOB  apolipoprotein B  
APOE apolipoprotein E 
ATPIII Adult Treatment Panel III 
BMI  body mass index 
bp base pair 
CAC coronary artery calcium 
CHD coronary heart disease 
CI confidence interval 
CRP C-reactive protein 
CVD cardiovascular disease 
DNA deoxyribonucleic acid 
EDTA ethylenediaminetetraacetic acid 
F11R F11-receptor 
FCHL familial combined hyperlipidemia 
GWA genome-wide association 
HDL high density lipoprotein 
HR hazard ratio 
HSDS Helsinki Sudden Death study 
ICD international classification of diseases 
IL6 interleukin 6 
kb kilobase 
LD linkage disequilibrium 
LDL low density lipoprotein 
LDLR low density lipoprotein receptor 
Mb megabase 
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MDA multiple displacement amplification 
MetS metabolic syndrome 
MI myocardial infarction 
mRNA messenger-RNA 
OR odds ratio 
PAD peripheral arterial disease 
PCR polymerase chain reaction 
RNA ribonucleic acid 
SCD sudden cardiac death 
SD standard deviation 
SMC smooth muscle cells 
SNP single nucleotide polymorphism 
T2DM type 2 diabetes mellitus 
TC total cholesterol 
TG triglycerides 
ULSAM Uppsala Longitudinal Study of Adult Men 
USF1 upstream transcription factor 1 
WGA whole-genome amplification 
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1 INTRODUCTION 
Cardiovascular diseases (CVD), which involve the heart, brain and peripheral 
circulation, affect millions of people worldwide, and are among the leading causes 
of death and disease burden both in high-income and low-income countries (Lopez 
et al. 2006). Along with several environmental and biochemical risk factors, disease 
susceptibility is modified by a genetic predisposition (Stegmayr et al. 1997; 
Kuulasmaa et al. 2000; Flossmann et al. 2004; Yusuf et al. 2004; Yarnell et al. 2005; 
Goldstein et al. 2006; Mayer et al. 2007). This genetic background is evidenced by 
familial aggregation of the disease, and family and twin studies have proposed that 
genetic factors explain 17 to 61% of the observed variation in CVD mortality or 
morbidity in the study populations (Bak et al. 2002; Zdravkovic et al. 2002; Fox et 
al. 2003; Fischer et al. 2005; Moskau et al. 2005; Wienke et al. 2005). 
Understanding how genetic variation in individuals and populations contributes to 
the biological pathways and mechanisms leading to CVD has been a subject of an 
intense research. Prospects for successful gene identification have been hindered by 
the complex nature of the disease; whereas in monogenic disorders variation(s) in a 
single gene locus with high penetrance results in a disease and the Mendelian 
segregation of the risk allele is observable in pedigrees, common complex diseases 
such as CVD are characterized by low penetrance, locus heterogeneity, epistasis, 
and variation in the disease phenotype (Lander and Schork 1994; Risch 2000).  
Appropriate selection of genetic markers and study samples can greatly aid 
dissection of the genetic background of a complex disease. The utility of isolated 
populations, such as Finland, is not necessarily limited to the mapping of rare 
diseases, but complex disease research can also greatly benefit from their features 
(Wright et al. 1999; Heutink and Oostra 2002; Service et al. 2006). Furthermore, 
increased information on single nucleotide polymorphisms (SNPs) and their 
haplotype-tagging properties in public databases ("The International HapMap 
Project"  2003), as well as improved multiplexing in SNP genotyping platforms have 
facilitated research (Robinson and Speed 2007; Steemers and Gunderson 2007). 
Methods for amplifying DNA at the whole genome level have also appeared 
(Hawkins et al. 2002), and we evaluated the utility of one of these amplification 
methods in SNP genotyping of a population based CVD study sample. 
Several genome-wide linkage or association studies have tried to identify genomic 
regions harboring genes contributing to CVD (Pajukanta et al. 2000; Francke et al. 
2001; Broeckel et al. 2002; Harrap et al. 2002; Chiodini and Lewis 2003; Hauser et 
al. 2004; Helgadottir et al. 2004; Wang et al. 2004; Samani et al. 2005; Wang et al. 
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2005; Engert et al. 2007; Larson et al. 2007; Matarin et al. 2007; Nilsson-Ardnor et 
al. 2007; O'Donnell et al. 2007; Samani et al. 2007). Additionally, numerous 
small-scale and large-scale candidate gene studies have examined the effect of 
various genes from the lipid and inflammation related pathways on CVD morbidity 
and mortality. In this work, we studied a particularly interesting candidate gene for 
CVD; the upstream transcription factor 1 (USF1), originally implicated in the 
etiology of familial combined hyperlipidemia (FCHL) (Pajukanta et al. 2004). This 
gene encodes a ubiquitously expressed transcription factor, which participates in the 
regulation of the expression of several genes from lipid and glucose metabolism 
pathways (Pajukanta et al. 2004; Naukkarinen et al. 2005). The chromosomal 
location of the gene also coincides with a linkage peak from several type 2 diabetes 
mellitus (T2DM) studies (Hanson et al. 1998; Elbein et al. 1999; Vionnet et al. 
2000; Hsueh et al. 2003; Ng et al. 2004a; Xiang et al. 2004) and from a metabolic 
syndrome study (Ng et al. 2004b). These disorders, along with FCHL, are strongly 
associated with CVD (Goldstein et al. 1973b; Tuomilehto et al. 1996; Austin et al. 
2000; Isomaa et al. 2001; Lakka et al. 2002; Hopkins et al. 2003; Malik et al. 2004; 
Ninomiya et al. 2004; Huxley et al. 2006).  
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2 REVIEW OF THE LITERATURE 
2.1 The role of genetics in the etiology of disease 
Two major breakthroughs in the field of genetics in the mid-20th century were the 
determining of the three-dimensional structure of the DNA molecule by Francis 
Crick, James D. Watson, Rosalind Franklin, and Maurice Wilkins in 1953 (Watson 
and Crick 1953) and the solving of how triplet mRNA codons specify the twenty 
amino acids through the combined efforts of scientists in the 1960s (Crick et al. 
1961; Nirenberg and Matthaei 1961; Matthaei et al. 1962; Khorana 1968). Later, the 
first findings of disease-causing genes began to emerge: The discoveries of human 
oncogenes in 1981 were among the first reported (Perucho et al. 1981). The easy 
amplification of DNA by the polymerase chain reaction (PCR) (Mullis et al. 1986) 
in the 1980s greatly facilitated genetic research and the sequencing projects of 
eukaryotic genomes finally led to a successful completion of the Human Genome 
Project in 2003 (Lander et al. 2001; Waterston et al. 2002; International Human 
Genome Sequencing Consortium 2004). Together, these advances have enabled the 
present-day efforts of dissecting the genetic background of various diseases. 
The role of genetics greatly varies depending on the trait or disease. While in some 
diseases, such as in many diseases of the Finnish disease heritage (Norio 2003), genes 
are the sole determinants of illness, in others, such as some virus or bacterial 
infections, the impact of genes is trivial or absent and the illness is determined by the 
interaction of genes and environmental factors, or by environment alone. Furthermore, 
the gene defect(s) causing the disease might be acquired during life and be present in 
only few cells, like in some cancers, or they might be inherited and be present in all 
cells of the body. In addition, a disease can arise due to a chromosomal abnormality, a 
single mutation in a gene, or several mutations in many genes.  
Whatever the mechanisms leading to the genetic diseases are, elucidating their 
nature and biology is of great importance. Understanding how a genetic disorder 
arises, offers tools for genetic counseling, gene-therapy, pharmacogenomics, and 
medicine, which attempt to prevent and treat these diseases.  
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2.2 Strategies for identifying genes underlying complex traits 
Many genes responsible for monogenic (Mendelian) diseases have been identified in 
the past two decades by linkage analysis and positional cloning methods. Most 
diseases and traits, however, involve multiple genes and environmental influences 
and their genetic dissection has proved to be more challenging (Table 1). 
 
Table 1. Complicating factors in genetic studies of complex diseases 
Genetic factors 
Unknown mode of inheritance 
Unknown allele frequencies 
Genetic heterogeneity 
Epistasis 
Gene-environment interactions 
Phenotypes 
Difficulties in diagnosis and classification of the phenotype 
Variable expressivity of the phenotype 
Incomplete penetrance 
Late onset of diseases 
Pleiotropy 
Phenocopies 
Technical issues 
Completeness and usability of genetic data in public databases 
Affordable large-scale genotyping methods 
Statistical issues 
Limited statistical power 
Multiple testing 
Other 
Publication bias 
 
In monogenic disorders, variation(s) in a single gene locus with complete or high 
penetrance results in a disease, and the Mendelian segregation of the risk allele is 
observable in pedigrees. Distinguishing the genetic background contributing to a 
complex disease is more difficult (Lander and Schork 1994; Risch 2000); the onset 
of the disease is the result of several genes functioning together with environmental 
risk factors. The overall contribution of each gene can be small, the frequencies of 
the risk alleles vary from rare to common, and epistasis, locus heterogeneity, 
pleiotropy, and low penetrance further complicate the gene discovery. Variation in 
the disease phenotype also obscures its genetic research; complex diseases can vary 
 16 
in many instances, such as the age of onset, severity of symptoms, and in their 
etiological mechanisms. 
To minimize the effect of any factors complicating gene discovery, strategies for 
identifying genes underlying complex traits should include careful consideration of 
the most appropriate study samples, genetic markers, and analysis techniques 
depending on the disease or phenotype analyzed (Lander and Schork 1994; Risch 
2000; Glazier et al. 2002). 
2.2.1 Genome and its markers 
The studies of the inheritance of human disease were facilitated with the recognition 
that DNA sequence of the genome contains naturally occurring variation (Petes and 
Botstein 1977; Botstein et al. 1980). The later sequencing of the human genome 
(Lander et al. 2001; Venter et al. 2001; International Human Genome Sequencing 
Consortium 2004) further accelerated disease gene discovery by providing 
invaluable information about the loci and nature of various kinds of polymorphic 
genetic markers (Table 2). 
The human genome is estimated to contain around 20,000 protein coding genes, 
whose transcripts cover about 1.9% of the euchromatic genome (International 
Human Genome Sequencing Consortium 2004). In addition to protein coding exons, 
gene loci comprise introns, promoters, and other regulatory regions. Additionally, 
the end product of some genes is a RNA molecule, which is not translated into a 
protein. Instead, those RNA molecules act as transfer-RNA, ribosomal-RNA, or 
have regulatory functions. Mutations in these gene-containing DNA sequences arise 
spontaneously or are induced by mutagens and they can impair the normal function 
of the gene, which can occasionally lead to a less favorable or a beneficial 
phenotype. If these mutations occur in germline cells, they are passed on to 
offspring and create variation in the gene pool of the population, providing material 
for natural selection, genetic drift, and other evolutionary forces (Tishkoff and 
Verrelli 2003). Although changes that occur outside of the gene loci do not interfere 
with the gene function, they can be utilized in genetic research as markers for the 
more functionally relevant genetic variation (Palmer and Cardon 2005).   
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Table 2. Examples of variation in the human genome 
Variation Features Size 
Restriction fragment 
length polymorphisms 
(RFLP) 
Restriction enzymes cleave DNA at specific 
sequences producing fragments of DNA. 
Variation of the DNA sequence between 
individuals at the restriction site can be 
detected as differing fragment lengths in 
electrophoresis. 
Restriction sites from 4 to 12 bp 
Single nucleotide 
polymorphisms (SNP) 
A single nucleotide of the DNA sequence 
differs in comparison with a reference 
sequence. 
1bp 
Microsatellites Tandem arrays of repeat units Repeat units 1-6 bp length, copy number of repeats usually 10-30 
Minisatellites Tandem arrays of repeat units 
Repeat units 8-100 bp length, copy 
number of repeats from 5 to over 
1,000 
Structural/Copy number 
variation 
Insertions, deletions, translocations, 
inversions, and duplications of large 
segments of DNA sequence. Copy number 
variants are present at a variable copy 
number in comparison with a reference 
genome. 
From 1 kb to more than 3 Mb 
Aneuploidy A change in the number of chromosomes Whole chromosomes 
 
Insertion and deletion (INDEL) polymorphisms of the genome overlap several of the categories presented in 
this table; INDEL polymorphisms range from 1 to 10,000 bp in length and include expansions of 1-15 bp 
repeat units (Mills et al. 2006). 
Modified from Jobling et al. 2004 and Feuk et al. 2006. 
 
Small-scale variation in the DNA sequence involves one or few nucleotides, 
whereas large-scale mutations, such as duplications, inversions, deletions, and 
translocations, can involve large segments of the genome (Table 2). During the last 
few decades, the types of variations most rigorously studied have changed as the 
techniques for detecting genomic variation have evolved.  
Restriction fragment length polymorphisms were among the first markers used in 
disease gene discovery (Botstein et al. 1980), and they have also been widely used in 
paternity testing and in genetic fingerprinting in forensic science. Genetic research 
was further facilitated with the recognition of microsatellite markers (Weber and 
May 1989), which consist of repeating units of 1-4 base pairs in length and which 
have been especially useful in identifying disease-causing gene loci by linkage 
analysis in pedigrees. In present-day research, single nucleotide polymorphisms 
(SNP) and lately also copy number variation, have gained extensive attention 
(Landegren et al. 1998; Sebat et al. 2004; Redon et al. 2006). 
The human genome harbors over 11 million SNPs (over 6 million of which are 
validated) (dbSNP Build 128, accessed 28.11.2007), which most often display only 
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two different alleles. The effect of a SNP on the gene function varies depending on 
the location and nature of the SNP. For instance, an exonic SNP may alter the 
amino-acid sequence of the gene product and lead to impaired protein function, and 
a SNP residing in a promoter region of the gene may alter the rate of transcription.  
In genetic research, the detection of the functional SNP is greatly aided by genomic 
linkage disequilibrium: A new mutation arises in a DNA sequence where specific 
SNP alleles exist. This combination of SNP alleles, a haplotype, is then inherited as 
a unit from the parental genomes, unless a recombination event in meiosis breaks the 
linkage between the SNP alleles. Between closely located SNPs, a recombination 
event is rare and genetic linkage keeps specific SNP alleles together; as a result, 
haplotype-tagging SNPs that are screened in genetic association studies provide 
information about several other SNPs in the loci also (Johnson et al. 2001; Gabriel et 
al. 2002; "The International HapMap Project"  2003).    
Single nucleotide polymorphism studies have conventionally screened SNPs at one 
or several particular loci, perhaps after a whole-genome microsatellite screening has 
first identified this candidate region. In the last few years, however, whole-genome 
association scans using SNP arrays have also become feasible (Carlson et al. 2004; 
Hirschhorn and Daly 2005). 
Despite intense research, discovery of complex disease or phenotype associated 
SNPs has proved to be challenging and it has been suggested that effective research 
should also utilize larger scale structural variation of the genome (Sebat et al. 2004; 
Redon et al. 2006; Stranger et al. 2007). These copy-number variations include gains 
or losses of large segments of genomic DNA, and they may function in the etiology 
of a disease for example through altered gene dosage or disruption of gene-coding or 
regulatory sequences. Well-known CVD related genes with copy number variation 
include thrombomodulin and lipoprotein a (Pollex and Hegele 2007).   
When the objective is to identify new candidate loci for traits and diseases, a 
genome-wide linkage or association scan of genetic markers is the ideal study 
design. Often this is the case when the biological pathways leading to the disease are 
not known. If the molecular mechanisms involved in the etiology of the disease are 
established, however, then candidate genes can be examined for a marker-phenotype 
association (Tabor et al. 2002). Candidate genes and loci are also inspected after the 
initial genome-wide studies to identify functional variants of the region and to study 
the effect of the identified disease-causing variants at the population level. 
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2.2.2 Choosing the study sample 
In order to minimize the effect of factors obscuring gene discovery, careful 
consideration should be put into the selection of the optimal study sample in 
research of common, complex diseases. An important issue is the sample size, which 
has to measure up to the estimates from power calculations for the study (Risch and 
Merikangas 1996). The study sample also has to match the aim of the study, whether 
it is to find new candidate genes for a disease or to study previously identified genes 
more thoroughly. Replication of the findings in other, independent study samples is 
crucial (Lander and Kruglyak 1995), although the reasons for lack of replication can 
sometimes be related to heterogeneity between studies rather than to spurious initial 
associations (Sillanpää and Auranen 2004).  
Family-based study samples are often used in the earliest stages of a complex 
disease gene search (Burton et al. 2005). Familial aggregation of a disease, 
measured by recurrence risk ratios or correlation measures, provides indirect 
evidence of an existing genetic contribution, although non-genetic factors can also 
add to the aggregation (Lander and Schork 1994; Burton et al. 2005). Estimates of 
heritability, the proportion of phenotypic variance that is attributable to genetic 
variation among individuals, of a trait can be obtained for instance from twin studies 
(Lander and Schork 1994; Burton et al. 2005). Segregation analysis in families have 
traditionally examined whether genes with a large enough effect for their 
identification exist (Lander and Schork 1994; Burton et al. 2005). When evidence of 
a genetic influence has been obtained, the genomic location of specific genes 
contributing to the disease is screened for with linkage analysis (Dawn Teare and 
Barrett 2005). While linkage analysis may identify regions of the genome 
segregating with the disease in pedigrees, further fine-mapping studies of the regions 
are required to identify causative genes and variants. This is achieved with 
association analysis, linkage-disequilibrium mapping, or haplotype analysis, either 
in family-based study samples or in population-based study samples (Cordell and 
Clayton 2005).  
Due to improvements in genotyping platforms, population-based samples without 
information on family relations can nowadays also be used in genome-wide SNP 
association scans for disease-associated genomic regions (Carlson et al. 2004; 
Hirschhorn and Daly 2005). In contrast to a genome-wide approach, if the molecular 
mechanisms behind the disease are known, genetic variation at candidate gene loci 
can be tested for disease association in case-control samples (Tabor et al. 2002). 
Population-based case-control studies circumvent some of the problems arising in 
family-based studies. For instance, diseases with late onset are more easily studied 
with a case-control approach where the availability of DNA usually is not a limiting 
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factor. Conversely, false positive associations due to multiple testing are a major 
problem in genome-wide SNP scans of case-control samples (Storey and Tibshirani 
2003; Carlson et al. 2004). Bias introduced by population stratification is an 
additional difficulty complicating case-control studies (Marchini et al. 2004).  
When disease-associated genetic variants have been identified with family-based or 
case-control studies, their impact on the morbidity of the general population can be 
examined in cohort studies (Manolio et al. 2006). In prospective cohort studies 
participants are usually examined at baseline, after which they are followed for a 
time. Often participants are also invited for examination at different time points 
during the follow-up period. The incidence of the disease during the follow-up is 
recorded and its association with genetic variation is studied. Cohort studies are not 
ideal for rare diseases since a large number of participants is needed to gain enough 
cases for analysis; for those diseases a case-control approach is more appropriate 
(Cardon and Bell 2001; Manolio et al. 2006).  
The selection of controls in cohort studies is less prone to bias than in case-control 
studies, since those who have not taken ill during the follow-up represent controls in 
the analysis (Manolio et al. 2006). A case-cohort study is a special type of a cohort 
study where data is analyzed only from those who developed the disease of interest 
during the follow-up and from a randomly selected subcohort from the original 
follow-up sample (Figure 1). This type of study was originally designed as an 
alternative way of conducting large survey studies where it is too expensive and 
time consuming to analyze all data from all participants. 
The effect of the disease-causing genetic variation at the cellular level can be 
examined for example with gene expression microarrays and proteomics (Lockhart 
and Winzeler 2000; Sellers and Yates 2003). The aim in these studies is often to 
investigate whether a specific polymorphism affects the amount or activity of the 
gene’s mRNA, or whether an effect on the protein product of the gene occurs. 
Expression analyses can also reveal disease-causing genes through abnormal 
patterns of protein expression in those who have the disease (Lockhart and Winzeler 
2000; Sellers and Yates 2003). 
 
 
 
 
 
 
 21 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A case-cohort study. After a follow-up, cases of interest are identified from 
the original follow-up cohort and are selected for genotyping and analyses. A 
random subcohort is also selected from the follow-up cohort to be used as a 
comparison group in the time-to-event analysis. These subcohort members may 
include some cases, as cases are eligible for the subcohort selection as well. This 
way, the subcohort represents the original follow-up cohort. 
 
In all study designs, a prudent choice of study population can reduce the genetic and 
environmental heterogeneity hampering the discovery of complex disease genes 
(Wright et al. 1999; Peltonen et al. 2000). Population isolates represent a more 
homogenous population to sample from, and they have more than proven their value 
in studies of Mendelian diseases (Peltonen et al. 1999). Features of these special 
populations, such as Finland, can facilitate genetic research of complex diseases as 
well: Uniform environmental and lifestyle-related risk factors may aid the detection 
of genetic risk factors contributing to the disease in reasonable-sized study samples 
(Peltonen et al. 2000). Furthermore, isolates are more likely to possess the same set 
of predisposing genes and alleles due to founder effect, genetic bottlenecks, and/or 
reduced migration (Wright et al. 1999; Peltonen et al. 2000). Population 
stratification, which may lead to false gene-disease associations in case-control 
studies, is also less likely to be present (Shifman and Darvasi 2001; Cardon and 
Palmer 2003). Another important advantage of population isolates is increased 
linkage disequilibrium (LD) present in their genomes (Service et al. 2006). Until 
resequencing of the entire gene loci and their surroundings becomes feasible for 
Time
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and baseline measurements Follow-up period
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follow-up data, 
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Genotyping and analyses
Disease event 
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large study samples, a gene-disease association can only be observed by genotyping 
a causative variant or a variant in high LD with it. Genome-wide association (GWA) 
scans in population isolates consequently require fewer genotyped markers, or 
capture more genomic variation through haplotype blocks with the same amount of 
genotyped markers, than GWA scans in outbred populations (Service et al. 2006). 
High LD can, on the other hand, complicate the identification of a causative gene 
variant and fine-mapping studies might therefore require the utilization of more 
outbred populations (Jorde 2000).  
2.2.3 Amount of DNA as a limiting factor in studies 
In addition to other genetic and environmental factors, genetic research is sometimes 
complicated by the amount of DNA available for the study. In most genetic studies 
the DNA to be genotyped is extracted from whole blood samples. While DNA yield 
from the blood varies with different storage conditions and DNA extraction 
methods, also natural variation between individuals occur (Cushwa and Medrano 
1993; Nederhand et al. 2003; Alanne et al. 2004). If this variation is dependent on 
the health status of an individual as suggested (Alanne et al. 2004), selection of 
samples based on the amount of DNA available can introduce a bias to the study 
from the beginning.   
Whole genome amplification of low-yield DNA samples prior to genotyping can 
provide a solution for preventing a DNA amount related bias (Hawkins et al. 2002). 
Several amplification methods exist, including degenerate oligonucleotide primed 
PCR (DOP–PCR) (Telenius et al. 1992; Cheung and Nelson 1996), primer extension 
preamplification (PEP) (Zhang et al. 1992; Dietmaier et al. 1999), and multiple 
displacement amplification (MDA) (Dean et al. 2001; Lovmar and Syvänen 2006). 
The MDA method (Figure 2) has stood out in comparison with other amplification 
methods providing good genomic coverage, high call rates, and reliable genotypes, 
while still having the lowest amplification bias (Lovmar and Syvänen 2006). 
Utilizing this method in genetic studies would aid the genotyping of otherwise 
non-genotypable low-yield DNA samples. Systematic quality control should be, 
however, conducted in order to identify possible spurious genotypes produced.  
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Figure 2. Whole genome amplification by the multiple displacement amplification 
(MDA) method. Random hexamers act as primers, annealing to complementary 
sequences in the single-stranded DNA molecule. The primers are elongated by DNA 
polymerase activity and in the process the 5’ ends of the elongated strands are 
displaced by upstream strands growing in the same direction. These displaced 
strands serve as templates for new priming events in the opposite direction. As the 
new priming events and strand displacements take place, an expanding 
hyperbranched network is formed, generating a massive amount of copies of the 
original DNA. Modified from Lage et al. 2003 and Lovmar and Syvänen 2006.  
 
2.3 Overview of atherosclerosis and cardiovascular disease 
Common, complex forms of cardiovascular disease, such as coronary heart disease 
and stroke (Table 3), present a great health burden on modern societies. In both 
high-income and low-income countries, cardiovascular diseases were among the 
leading causes of death and disease burden in 2001 (Lopez et al. 2006). In 2005, the 
3’5’
3’5’
3’5’
3’5’
3’5’
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statistical database of the Finnish National Cardiovascular Disease Register (Mähonen 
et al. 2000) recorded 1743 coronary events (I20-I25) per 100,000 inhabitants in the 
age group of 25-74. The number of patients and deaths due to ischemic stroke (I63) 
was 309 per 100,000 inhabitants. First signs of these common diseases appear as early 
as in the childhood (Berenson et al. 1998; Strong et al. 1999). 
 
Table 3. Cardiovascular diseases relevant to this thesis, according to the ICD-10 
classification 
Diseases of the circulatory system (I00-I99) 
Ischaemic heart diseases I20-I25 
 Angina pectoris I20 
 Acute myocardial infarction I21 
 Subsequent myocardial infarction I22 
 Certain current complications following acute myocardial infarction I23 
 Other acute ischaemic heart diseases I24 
 Chronic ischaemic heart disease I25 
Cerebrovascular diseases I60-I69 
 Cerebral infarction I63 
Diseases of arteries, arterioles and capillaries I70-I79 
 Atherosclerosis I70 
 Aortic aneurysm and dissection I71 
 Arterial embolism and thrombosis I74 
 
 
Cardiovascular diseases usually result from a complex series of events affecting 
arterial blood vessels; atherosclerosis. Atherosclerotic plaque formation begins with 
the accumulation of lipoprotein particles, such as low density lipoprotein (LDL) and 
lipoprotein a (Lp(a)), in the intima layer of the arteries (Figure 3). These lipoproteins 
transmigrate to the intima through the endothelium at sites of lesion predilection, 
which are determined by characteristics of the blood flow in the arteries. When the 
circulating levels of these lipoproteins are raised, the rate of their accumulation in 
the subendothelial matrix is also increased. In the intima, the lipoproteins undergo 
oxidation and other modifications, such as aggregation, lipolysis, and proteolysis. 
These modifications subsequently stimulate the endothelium to produce other 
molecules involved in the plaque formation. High-density lipoprotein (HDL) has an 
anti-atherogenic role in these initial processes: it removes excess cholesterol from 
the peripheral tissues and also inhibits lipoprotein oxidation. In response to the 
accumulation of modified lipoproteins in the vessel wall, endothelial cells produce 
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pro-inflammatory molecules. This production of molecules can further be modified 
by other factors, such as sex hormones, infection, diabetes, and homocysteine levels. 
The inflammation-related molecules, which include adhesion molecules, mediate the 
transmigration of monocytes to the site of the lipid accumulation. The migrated 
monocytes proliferate and differentiate into macrophages. These macrophages, with 
the help of various receptors and ligands, take up the extensively modified lipid 
particles, leading to the formation of foam cells. As these cells die by apoptosis, the 
lipid-filled contents of them contribute to the necrotic core of the lesion. Smooth 
muscle cells (SMCs) further increase the size of the atherosclerotic plaque: they 
migrate to the site of the lesion, stimulated by cytokines and growth factors, which 
are expressed by macrophages. These intimal SMCs then contribute to the formation 
of a fibrous cap by secreting fibrous elements and extracellular matrix. Processes 
leading to the development of a fibrous lesion are further modified by risk factors 
such as hormones, elevated homocysteine, hypertension, and infection. (Lusis 2000) 
Products of the inflammatory cells in atherosclerotic lesions participate in 
maintenance and degradation of the fibrous cap of the plaque. A rupture of the cap 
and subsequent thrombosis can lead to acute coronary and cerebrovascular events, 
and plaque composition and vulnerability are important determinants of future 
complications. Stability of an atherosclerotic lesion is influenced by several factors, 
including proteinases that degrade extracellular matrix, calcification of the lesion, 
factors contributing to inflammation, and also infection. A plaque rupture leads to a 
coagulation cascade, which results in the formation of a thrombus or a blood clot. 
Tissue factor, plasminogen activator, and other important molecules mediate these 
events. (Lusis 2000) 
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Figure 3. A simplified representation of the development of atherosclerotic plaques. 
Lipoprotein accumulation in the subendothelial matrix is followed by recruitment of 
monocytes and smooth muscle cells. Foam-cell formation, inflammation reactions, 
and apoptosis contribute to the formation of a lipid-rich, necrotic core of the lesion. 
Development of a fibrous cap and its subsequent rupture can lead to formation of a 
thrombus and possibly in ischemic cardiovascular events. Modified from Lusis 2000 
and Watkins and Farrall 2006.  
 
The atherosclerotic processes usually take decades to develop into a phase where a 
vessel narrowing or occlusion by thrombosis causes clinical complications. In 
ischemic heart disease, or coronary heart disease (CHD), atherosclerosis affects the 
arteries of the heart. Atherosclerosis can also affect arteries of the brain 
(cerebrovascular diseases), or the circulatory system outside of the brain and heart 
(peripheral vascular disease). The clinical complications caused by atherosclerosis 
are due to shortage of oxygen in the tissues whose oxygen is provided by the 
occluded blood vessels. 
Narrowed coronary arteries fail to supply the tissue of the heart with an adequate 
amount of blood and oxygen. Angina pectoris, chest pain with variable severity, is a 
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common symptom of the restricted blood flow in the coronary arteries and can present 
both stable and unstable forms (Grech and Ramsdale 2003). The most severe outcome 
of coronary atherosclerosis is myocardial infarction (MI) (Achar et al. 2005), preceded 
by a rupture of an atherosclerotic plaque and a formation of a thrombus. In MI, tissue 
of the heart suffers severe damage due to interrupted blood flow and oxygen supply. 
MI is a life-threatening event, requiring immediate medical care. 
Besides MI, another acute outcome of atherosclerosis of the arteries is ischemic stroke, 
where blood flow in the brain tissue is decreased or disrupted. Although ischemic 
stroke usually is a result of a local damage to the vessel wall from atherosclerosis, 
these strokes can also result from an embolus of cardiac origin. Cerebral infarction is a 
severe consequence of the impaired supply of oxygen and results in permanent cellular 
damage. The extent of the damage is dependent upon the duration of the ischemia and 
the availability of collateral circulation. (Frizzell 2005) 
In peripheral arterial disease (PAD), blood flow is restricted in narrowed or 
occluded arteries leading to the stomach, arms, legs, feet, or kidneys. Intermittent 
claudication, a condition where muscle pain or cramping in legs or arms is triggered 
by activity, is a common symptom of the restricted circulation in the limbs (Leng et 
al. 1996).  
Aortic atherosclerotic disease is a significant risk factor for embolic stroke and 
peripheral embolization, especially when there are severe atherosclerotic plaques in 
the aorta. Aortic plaques can also be seen as an expression of generalized 
atherosclerosis and they correlate with higher prevalence of CHD. (Kronzon and 
Tunick 2006) 
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2.3.1 Cardiovascular risk factors 
Several environmental, biochemical, and genetic risk factors contribute to the risk of 
CVD (Table 4) (Yusuf et al. 2004; Goldstein et al. 2006). 
 
Table 4. Risk factors for cardiovascular disease. 
Risk factor Environmental risk factor 
Physiological or 
biochemical risk 
factor 
Genetic risk factor 
    
Alcohol consumption X  X 
Smoking X  X 
Lack of physical activity X  X 
Diet X  X 
Obesity, body composition  X X 
Diabetes and blood glucose levels  X X 
Hypertension  X X 
Low blood HDL levels  X X 
High blood LDL levels  X X 
High blood triglyceride levels  X X 
Thrombotic factors  X X 
Family history of CVD   X 
Male gender   X 
Age   (X) 
 
Some of the CVD susceptibility is due to age, gender, and family history of CVD, 
and cannot be modified by lifestyle changes. Adjusting dietary habits, exercise, and 
cutting down on smoking and alcohol consumption, however, can reduce the risk of 
CVD (Yusuf et al. 2004; Goldstein et al. 2006). These lifestyle changes may reduce 
the risk of CVD through changes in some conventional physiological or biochemical 
risk factors, such as levels of serum lipoproteins, obesity, or hypertension. 
Lipoproteins such as LDL have a significant role in the formation of atherosclerotic 
plaques, and clinical trials have shown the beneficial effect of lipid lowering 
medication on the risk of CVD. Other major components of a lesion and thrombus 
formation have also associated with CVD in epidemiological studies; these risk 
factors include elevated levels of inflammatory molecules such as C-reactive 
protein, haemostatic factors (e.g. fibrinogen and plasminogen activator inhibitor type 
1) and homocysteine. (Lusis 2000) 
 29 
Many of the established risk factors for CVD have a strong genetic component. 
Recent studies have also suggested that many of the risk factors conventionally 
considered as solely environmental (Table 4), might have a genetic predisposition 
(Whitfield et al. 2004; Ingelsson et al. 2007; Keskitalo et al. 2007; Uhl et al. 2007). 
Suggestive evidence for the role of infectious agents in atherosclerosis also exist 
(Fong 2002; Mussa et al. 2006). 
Individuals with common metabolic disorders, such as familial combined 
hyperlipidemia (FCHL) (Goldstein et al. 1973a) and the metabolic syndrome (MetS) 
(Reaven 1993; Eckel et al. 2005), are also at increased risk of CVD (Austin et al. 
2000; Voors-Pette and de Bruin 2001; Lakka et al. 2002; Hopkins et al. 2003; Malik 
et al. 2004).    
2.3.2 Phenotypic overlap between cardiovascular disease, metabolic 
syndrome and familial combined hyperlipidemia 
Extensive phenotypic overlap exists between MetS (Reaven 1993; Alberti et al. 
2005; Eckel et al. 2005), FCHL (Goldstein et al. 1973a), and type 2 diabetes mellitus 
(T2DM) (Alberti and Zimmet 1998), which all predispose to premature CVD 
(Tuomilehto et al. 1996; Austin et al. 2000; Voors-Pette and de Bruin 2001; Lakka 
et al. 2002; Hopkins et al. 2003; Malik et al. 2004; Huxley et al. 2006). T2DM 
primarily involves insulin resistance and hyperglycemia, but also often associates 
with hypertension, obesity, and dyslipidemias (Alberti and Zimmet 1998). FCHL, 
first described in 1973, is a dyslipidemia characterized by elevated serum total 
cholesterol, triglycerides, or both (Goldstein et al. 1973a). Diagnostic criteria of 
FCHL also include at least one affected first degree relative and usually also 
premature CHD of the proband.  
MetS, a common metabolic disorder, is characterized by a clustering of CVD risk 
factors (Alberti et al. 2005; Eckel et al. 2005). The prevalence of MetS, which is 
highly age-dependent, has greatly increased during the last few decades alongside 
with the increasing rates of obesity and T2DM. Although MetS is more common in 
the older age-groups, the disorder and biomarkers of an increased risk of CVD can 
be found among obese children and adolescents. 
Several definitions for MetS exist, proposed by the World Health Organization 
(WHO), National Cholesterol Education Program’s Adult Treatment Panel III 
(NCEP:ATP III), the European Group for the Study of Insulin Resistance (EGIR), 
and the International Diabetes Federation (IDF). These definitions differ in their 
cut-off point values for the components of MetS, and may also have their own ways 
of combining the components to define MetS. Most of them do, however, agree on a 
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central set of criteria, which include impaired glucose tolerance, impaired fasting 
glucose or insulin resistance, dyslipidemia, central obesity, and hypertension. 
Overabundance of free fatty acids plays a central role in the pathophysiology of 
MetS. Along with other factors, it contributes to several unfavorable outcomes; 
increased production of glucose by the liver, reduction in HDL cholesterol and 
increase in small dense (more atherogenic) LDL, hypertension, and increases in 
proinflammatory cytokines.  (Eckel et al. 2005) 
Many of the components of MetS are established risk factors for CVD, and they also 
include features associated with T2DM (impaired glucose tolerance and impaired 
fasting glucose). This overlap between T2DM, FCHL, and MetS suggests that the 
same genetic determinants may contribute to the pathology.  
2.3.3 Gender-specific aspects of cardiovascular disease 
In the past, cardiovascular disease in men gained most of the attention and research 
was often conducted using study samples consisting of only men (Barrett-Connor 
1997). As previously, in the younger age-groups the majority of patients whom die 
due to CVD today are still men (Tunstall-Pedoe 1998; Tilastokeskus 2007a). 
Women, however, outnumber men in CVD deaths in the older age groups (Figure 4) 
(Tunstall-Pedoe 1998; Tilastokeskus 2007a). In Finland, cardiovascular disease is 
correspondingly shifting from being a disease of middle-aged men to a disease of 
elderly women (Kattainen et al. 2006).  
Women undergo CVD at a later age compared to men (Figure 4). In 2006, 20% of 
men who died from CVD were under 65, 42% were under 75, and 79% were under 
85 (Tilastokeskus 2007a). Among women, the corresponding figures were 5%, 13%, 
and 48%. Mortality of women began to increase at the age of 65 and the number of 
deaths was highest among 85 year olds, whereas among men the number of CVD 
deaths began to rise at the age of 50 and was highest at the age of 75 (Figure 4). 
Importantly, in all age-groups the proportion of men with CVD death out of all men 
at risk of death was higher than the proportion of women with CVD death out of all 
women at risk of death (Figure 5) (Tilastokeskus 2007b). As morbidity from CVD 
strongly correlates with mortality from it (Tunstall-Pedoe et al. 1994); the risk of 
incident CVD and related death is higher among men than among women, 
throughout life (Figure 5) (Tunstall-Pedoe 1998).    
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Figure 4. Number of deaths due to ischemic heart disease or cerebrovascular disease 
in Finland by sex and age, 1996 and 2006. (Tilastokeskus 2007a) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Mortality (% of population) due to ischemic heart disease or 
cerebrovascular disease in Finland by sex and age group, year 2006. (Tilastokeskus 
2007a; Tilastokeskus 2007b) 
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Distribution of cardiovascular risk factors is often different among men and women 
(Barrett-Connor 1997; Weiss et al. 2006), and usually men possess the more 
unfavorable risk profile (Barrett-Connor 1997). Variation in environmental risk 
factors is, however, insufficient to fully explain the contrast of the frequency of 
CVD between the two sexes (Barrett-Connor 1997). Some differences are likely to 
be explained by the contribution of tissue-specific hormonal environments and gene 
expressions, which are dissimilar in men and women (Rinn and Snyder 2005). Sex 
hormones and their receptors play an important part in the etiology of CVD, 
participating in the activation of CVD-related gene expression in the smooth muscle 
cells, arterial endothelium, and liver (Barrett-Connor 1997; Mendelsohn and Karas 
2005; Rinn and Snyder 2005).  
2.4 Genetics of cardiovascular disease 
The majority of CVD events result from a complex interplay between several genes 
and environmental risk factors (Figure 6), although rare monogenic forms of 
cardiovascular disease also exist. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. CVD is a complex disease. Association between a particular genetic risk 
factor and the disease can be in part due to intermediate phenotypes increasing 
susceptibility. Detection of the association between a genetic risk factor and the 
disease (depicted with a dashed line) is obscured by other genetic factors, and 
environmental factors contributing to the disease.  
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A large portion of the risk for CVD is considered to be explained by genetic factors 
(Zdravkovic et al. 2002; Flossmann et al. 2004; Fischer et al. 2005; Moskau et al. 
2005; Wienke et al. 2005) (Table 5). For relatives of a CHD patient, the risk of CHD 
can be twofold (Jousilahti et al. 1996; Lloyd-Jones et al. 2004) and the risk of a 
stroke is also increased (Kiely et al. 1993; Schulz et al. 2004). A proportion of the 
increased CVD risk may be explained by genetic factors that influence intermediate 
CVD phenotypes, such as LDL or HDL levels (Table 5). 
 
Table 5. Heritability estimates of stroke, CHD, and their risk factors  
 
Trait Heritability Reference 
T2DM / glucose / insulin 0.24-0.85 (Poulsen et al. 1999; Hanson et al. 2001; McQueen et al. 2003; 
Mills et al. 2004; Souren et al. 2007) 
MetS 0.38-0.61 (McQueen et al. 2003; Bayoumi et al. 2007) 
Obesity/BMI 0.31-0.94 (O'Connell et al. 1988; Brown et al. 2003; McQueen et al. 
2003; Mills et al. 2004; Souren et al. 2007) 
Hypertension / blood 
pressure 
0.17-0.49 (Brown et al. 2003; McQueen et al. 2003; Mills et al. 2004) 
Total cholesterol 0.32-0.75 (O'Connell et al. 1988; Heller et al. 1993; Mills et al. 2004; 
Souren et al. 2007) 
Triglycerides 0.28-0.72 (Heller et al. 1993; McQueen et al. 2003; Mills et al. 2004) 
LDL cholesterol 0.43-0.78 (O'Connell et al. 1988; Mills et al. 2004; Souren et al. 2007) 
HDL cholesterol  0.42-0.79 (O'Connell et al. 1988; Heller et al. 1993; McQueen et al. 
2003; Mills et al. 2004; Souren et al. 2007) 
apoB 0.51-0.78 (Heller et al. 1993) 
Coronary heart disease / 
atherosclerosis 
0.05-0.84 (Zdravkovic et al. 2002; Fischer et al. 2005; Wienke et al. 
2005; Cassidy-Bushrow et al. 2007) 
Stroke 0.17-0.32 (Bak et al. 2002) 
 
 
Several linkage studies have scanned the human genome in order to find 
chromosomal regions contributing to CVD (Pajukanta et al. 2000; Francke et al. 
2001; Broeckel et al. 2002; Harrap et al. 2002; Chiodini and Lewis 2003; Hauser et 
al. 2004; Wang et al. 2004). Replication of the identified loci has been difficult and 
pinpointing the causative gene has often been challenging (Chiodini and Lewis 
2003; Wang et al. 2004). Part of this challenge is explained by limitations of the 
linkage approach: When several loci contribute to the disease susceptibility and 
those with modest effects are hard to detect by linkage, background noise may cause 
different selection of loci to be identified in different studies (Chiodini and Lewis 
2003; Watkins and Farrall 2006). Recently, genome-wide association scans 
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searching for gene loci contributing to CVD have also become feasible (Larson et al. 
2007; O'Donnell et al. 2007).  
2.4.1 Monogenic and multifactorial forms of cardiovascular disease and 
CVD related traits  
Many studies have had success in finding genetic loci contributing to specific risk 
factors for CVD, instead of the complex phenotype for CVD (Watkins and Farrall 
2006). Several lipid metabolism related disorders are monogenic diseases that 
increase the risk for CVD substantially (Nabel 2003; Watkins and Farrall 2006). 
These include familial hypercholesterolemia (mutated gene LDLR) (Goldstein and 
Brown 1979), familial defective apolipoprotein B-100 (mutated gene APOB) 
(Innerarity et al. 1987; Soria et al. 1989), and sitosterolemia (mutated genes ABCG5 
and ABCG8) (Berge et al. 2000; Lee et al. 2001) (Table 6). One person out of five 
hundred carries the LDLR gene mutation, and only one in a million is a 
homozygote, who develops severe atherosclerosis and suffers a myocardial 
infarction early in life (Nabel 2003; Watkins and Farrall 2006). Patients affected 
with sitosterolemia are even fewer, less than 100 have been reported in literature 
worldwide (Lee et al. 2001).  
Another suggested risk factor for myocardial infarction, stroke, or especially venous 
thromboembolic disease is factor V Leiden mutation, which prevents the 
degradation of factor V and enhances clot formation (Bertina et al. 1994; Nabel 
2003). The frequency of factor V Leiden mutation in northern Europeans is 2-7%. 
Risk of thromboembolic events is also increased in homocystinuria, a disorder with 
an incidence of approximately 1 in 335,000 (Naughten et al. 1998).  
Monogenic diseases that elevate or lower blood pressure also exist (Table 6). 
Studies on these monogenic disorders have identified targets for developing for 
instance treatments for high serum lipids. They have also provided valuable 
information on the biological pathways and mechanisms of diseases for the 
common, complex forms of CVD. 
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Table 6. Examples of genes associated with CVD or related traits with Mendelian 
inheritance 
Syndrome Mechanism Reference 
Hypercholesterolemia, 
autosomal dominant (Familial 
hypercholesterolemia) 
Nonfunctional receptor of LDLR fails to take 
up plasma cholesterol 
(Goldstein and Brown 
1979) 
Hypercholesterolemia, 
autosomal dominant, type b 
(apolipoprotein b-100, familial 
ligand-defective) 
Clearance of plasma LDL is decelerated as 
binding of apoB-100 to LDLR receptors is 
reduced due to mutations in the APOB gene 
(Innerarity et al. 1987; 
Soria et al. 1989) 
Sitosterolemia Mutated forms of ABCG5 and ABCG8 genes predispose to sterol overaccumulation 
(Berge et al. 2000; Lee 
et al. 2001) 
Hypercholesterolemia, 
autosomal dominant 
Missense mutations, probably gain-of-function 
mutations, in the PCSK9 gene cause 
hypercholesterolemia 
(Abifadel et al. 2003) 
Tangier disease 
Accumulation of cellular cholesterol and low 
plasma HDLc levels due to mutations in the 
ABCA1 gene 
(Bodzioch et al. 1999; 
Brooks-Wilson et al. 
1999; Rust et al. 1999) 
Homocystinuria Increased risk for thromboembolic events due to mutated CS gene 
(Naughten et al. 1998; 
Yap 2003) 
Thrombophilia due to deficiency 
of cofactor for activated protein 
c, Leiden type 
Mutated F5 gene prevents the degradation of 
factor V and enhances clot formation (Bertina et al. 1994) 
Cortisol 11-beta-ketoreductase 
deficiency (Apparent 
mineralocorticoid excess) 
Mutations in the HSD11B2 gene lead to 
increased blood pressure (White et al. 1997) 
Glucocorticoid-remediable 
aldosteronism 
CYP11B2 gene is fused with the CYP11B1 
gene, which leads to changes in control of gene 
expression and thus increased blood pressure 
(Lifton et al. 1992) 
CAD, autosomal dominant, 1 
(ADCAD1) 
Deletion in exon 11 of the MEF2A gene result 
in loss of function of transcriptional activation 
activity 
(Wang et al. 2003) 
(Later argued against 
by (Weng et al. 2005)) 
 
Common forms of CVD are characterized by the interplay of several environmental 
risk factors and many genes with possibly multiple different alleles contributing to 
disease susceptibility (Lohmueller et al. 2003). Interesting candidate genes include 
signal molecules from inflammation pathways, apolipoproteins and other well known 
lipid metabolism related genes (Figure 3) (Casas et al. 2006; Watkins and Farrall 
2006). Since many of the genes and pathways contributing to the progression and 
emerging of CVD are related (for example the impact of lipids and inflammation on 
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the atherosclerotic lesion), especially transcription factors regulating the expression of 
several genes are plausible candidate genes for CVD studies. 
Well-known genes implicated in the etiology of the common CVD include 
apolipoprotein genes, such as apolipoprotein E (APOE) and APOB genes, 
thrombosis and hemostasis related genes, such as fibrinogen, factor V, and 
prothrombin, and inflammation related genes, such as the interleukin-6 (IL6) gene 
(Table 7). Many genes have also been suggested in the etiology of T2DM, and some 
gene associations, such as peroxisome proliferator-activated receptor- (PPARG) 
and transcription factor 7-like 2 (TCF7L2), have been confirmed in multiple 
samples. New candidate genes for CVD and its risk factors are located with 
traditional methods and with emerging large-scale genome-wide association scans 
(Helgadottir et al. 2007; Larson et al. 2007; Levy et al. 2007; McPherson et al. 2007; 
Samani et al. 2007). Candidate genes are further studied in large international 
collaborations (Evans et al. 2005; Danesh et al. 2007).  
 
Table 7. Examples of genes suggested in the genetics of common forms of CVD or 
its risk factors 
Gene Cardiovascular outcome/risk factor Reference 
ABCA1 Dyslipidemia, CHD (Tregouet et al. 2004) 
ACE CHD, MI (Morgan et al. 2003) 
AGT Hypertension (Sethi et al. 2003) 
ALOX5AP MI and stroke (Helgadottir et al. 2004) 
APOE Dyslipidemia, CHD, MI (Song et al. 2004) 
APOA5 Dyslipidemia (Martin et al. 2003b) 
APOB Dyslipidemia, CHD, MI (Chiodini et al. 2003) 
CETP Dyslipidemia, CHD (Boekholdt et al. 2005) 
F2 (Prothrombin) MI (Burzotta et al. 2004) 
F5 Venous thromboembolic events, MI, stroke (Kim and Becker 2003) 
Fibrinogen MI (Boekholdt et al. 2001) 
FTO Obesity  (Frayling et al. 2007) 
IL6 CHD, MI (Georges et al. 2001; Tanaka et al. 2005) 
INSIG2 Obesity (Herbert et al. 2006) 
MTHFR CHD (Klerk et al. 2002) 
PDE4D Stroke (Gretarsdottir et al. 2003) 
PPARG TD2M (Altshuler et al. 2000) 
SERPINE1  (PAI-1) MI (Boekholdt et al. 2001) 
TCF7L2 TD2M (Grant et al. 2006) 
Modified from Casas et al. 2006, Arnett et al. 2007, and Cambien and Tiret 2007. 
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2.4.2 Sex-specific differences in the genetics of cardiovascular disease 
As well as in sex-specific gene expression, the two sexes can also differ in regards to 
the heritability of CVD risk factors, such as LDL, HDL, and systolic blood pressure 
(Weiss et al. 2006). Correspondingly, studies on CVD have observed sex-specific 
results (Tentschert et al. 2003; Weiss et al. 2006). Sometimes these sex-dependent 
results may be due to complicating environmental factors which prevent detection of a 
genetic association in one of the sexes despite an existing association.  In some cases a 
risk increasing effect of a risk factor may be larger in one of the sexes; For instance 
low HDL levels or diabetes increase the risk of CVD especially among women 
(Barrett-Connor 1997; Dale et al. 2007). Hormone-replacement therapy at menopause 
does not necessarily decrease the risk of CVD among women (Waters et al. 2004), 
although it has been suggested that the onset of the therapy or the physiological 
differences between the arteries of women in different age groups have not sufficiently 
been accounted for in previous studies (Mendelsohn and Karas 2005). 
2.4.3 USF1 as a candidate gene for cardiovascular disease 
The disorders FCHL, metabolic syndrome, and type 2 diabetes are often implicated 
in cardiovascular disease (Genest et al. 1992; Tuomilehto et al. 1996; Austin et al. 
2000; Voors-Pette and de Bruin 2001; Lakka et al. 2002; Hopkins et al. 2003; Malik 
et al. 2004; Huxley et al. 2006). A chromosomal region at 1q21-23 has showed 
compelling evidence of linkage to these three disorders (Hanson et al. 1998; 
Pajukanta et al. 1998; Elbein et al. 1999; Vionnet et al. 2000; Hsueh et al. 2003; Ng 
et al. 2004a; Ng et al. 2004b; Xiang et al. 2004), and subsequently an interesting 
candidate gene within the region has been identified (Pajukanta et al. 2004). This 
gene encodes upstream transcription factor 1 (USF1). 
USF1 is a ubiquitously expressed transcription factor regulating transcription of 
several genes from the lipid and glucose metabolism pathways (Naukkarinen et al. 
2005) (Table 8). The genomic size of the gene encoding USF1 is 6.7 kb, it has two 
major splicing variants (Saito et al. 2003), and resides in chromosome 1q22-23 
(Figure 7 and Figure 8) (Shieh et al. 1993). 
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Figure 7. The chromosomal region containing USF1. Modified from the UCSC 
Genome Browser. 
 
 
 
 
 
 
 
 
 
 
Figure 8. The USF1 gene. The two common splicing forms of USF1 contain 11 
exons, from which seven or ten are translated into a protein sequence. Exon 4 of the 
gene contains an alternative splicing site and the exon is thus 31 bp shorter in the 
alternative splicing variant. Modified from the UCSC Genome Browser and Saito et 
al. 2003.  
 
The USF1 protein, which comprises 310 amino acids and contains a helix-loop-helix 
motif, binds an E-Box motif (5'-CACGTG-3') in the promoter regions of its target 
genes as a dimer with another USF1 or with a USF2 protein (Sawadogo 1988; 
Sawadogo et al. 1988; Gregor et al. 1990; Roy et al. 1991; Ferre-D'Amare et al. 
1994; Viollet et al. 1996). Besides USF2, USF1 possibly interacts with other 
proteins such as GTF2I, FOSL1, ESR1, and NFYA (Peri et al. 2003; Mishra et al. 
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2006; Stark et al. 2006). The Cha-protein has been indicated to regulate the activity 
of USF1 (Rodriguez et al. 2003). 
One of the cardiovascular-related genes regulated by USF1 is angiotensinogen 
(AGT), which participates in blood pressure regulation (Caulfield et al. 1994; Saito 
et al. 2003). In addition USF1 affects the expression of some important genes 
involved in cholesterol homeostasis and fatty acid synthesis, such as APOE and fatty 
acid synthase (FASN) (Casado et al. 1999; Salero et al. 2003; Naukkarinen et al. 
2005). Furthermore, USF1 has a role in the regulation of some inflammation related 
genes: hepcidin (Bayele et al. 2006), beta-2 microglobulin (Gobin et al. 2003), and 
metallothionein (Andrews 2000). See Table 8. 
The function of USF1 as a regulator of these and other important genes suggests 
USF1 is an important candidate gene for CVD. 
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3 AIMS OF THE STUDY 
When this study was initiated, the USF1 gene on chromosome 1q21-23 had been 
associated with familial combined hyperlipidemia in Finnish FCHL families 
(Pajukanta et al. 2004). USF1 was also known to regulate several genes involved in 
pathways relevant for cardiovascular disease. We thus sought to investigate the 
relation between allelic variation within USF1 and cardiovascular disease and its 
risk factors. The specific aims were, in our population-based study samples: 
 
1) To study a potential relationship between USF1 alleles and traditional 
cardiovascular risk factors such as serum lipid values, the metabolic 
syndrome, and body composition measurements (I, III). 
2) To further determine whether USF1 alleles affect atherosclerotic 
phenotypes at the target tissue level, i.e. the vessel wall (II). 
3) To examine if the allelic variants of USF1 affect the risk of a sudden 
cardiac death or a cardiovascular event at the population level (I-III). 
4) To investigate how the use of whole genome amplified DNA affects 
accuracy of genotyping when some of the study samples have a low yield of 
DNA (IV). 
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4 MATERIALS AND METHODS 
4.1 Table of materials and methods 
The details of the materials and methods used in this study are described in the 
original publications (I-IV) according to Table 9. 
 
 
Table 9. Materials and methods used in this study. 
Material or method Original publication 
Study samples  
ULSAM I 
HSDS II 
FINRISK III 
Whole genome amplified FINRISK samples IV 
Control DNA I, IV 
Definition of metabolic syndrome I 
Definition of cardiovascular disease I - III 
Definition and measurements of atherosclerosis II 
Measurements of lipid parameters  I, III 
Laboratory procedures  
DNA extraction I - IV 
DNA quantitation IV 
Polymerase chain reaction (PCR) I - IV 
Testing of DNA integrity IV 
Agarose gel electrophoresis I - IV 
Sequencing IV 
Allele-specific primer extension on microarrays II - IV 
Sequenom MALDI-TOF mass spectrometry II - IV 
Single-base primer extension assay with 
fluorescence polarization detection 
I 
Multiply-primed rolling circle DNA 
amplification 
III, IV 
Statistical methods  
SNP selection I - IV 
LD estimation I - III 
Haplotype estimation I - III 
Chi-squared tests I - III 
Analysis of covariance I, III 
Regression analysis II 
Time-to-event analysis I, III 
Mixed longitudinal analysis I 
Permutation of association I, III 
False discovery rate correction II 
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Table 9 continued. 
Material or method Original publication 
Analysis programs  
SNPSnapper II - IV 
Haploview I - III 
PHASE 2.11 I, III 
SpectroDESIGNER II - IV 
SpectroCALLER II - IV 
Primer3 II - IV 
Oligo Analyzer 3.0 II - IV 
QuantArray 3.0 II - IV 
GeneMapper 3.0 IV 
Sequencher 4.1.4  IV 
SAS for Windows (v8.2 & 9.1) I-III 
 
4.2 Study samples 
Three different population-based study samples were included in this study (Table 10). 
 
Table 10. Characteristics of the study samples. 
Characteristic ULSAM HSDS FINRISK 
Recruitment areas Uppsala county, 
Sweden 
Helsinki area, 
Finland 
5 regions of Finland 
Genotyped subjects (n) 2,322 700 2,225 
Age distribution at the baseline of the 
study (years) 
50 33-70 25-74 
CVD cases (n) 701 230 1,190 
Subjects free of CVD (n) 998 470 626 (the healthy 
subcohort) 
Proportion of men in the sample 100% 100% 69% 
Length of follow-up period (years) 32 no follow-up 7 and 10 
 
 
The Uppsala Longitudinal Study of Adult Men (ULSAM) was approved by the 
Ethics Committee of the Medical Faculty of Uppsala University, and the FINRISK 
studies were approved by the ethical committee of the National Public Health 
Institute. All ULSAM and FINRISK participants gave informed consent and the 
principles of the Helsinki Declaration were followed. The Ethics Committee of the 
Department of Forensic Medicine of the University of Helsinki approved the 
Helsinki Sudden Death Study (HSDS). Samples for the study of whole genome 
amplification were selected from the FINRISK study sample. 
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4.2.1 The ULSAM study sample (I) 
The ULSAM study sample consisted of 2,322 men born between 1920-1924 and 
living in Uppsala, Sweden, and recruited at the age of 50 (Table 10). The 
participants were followed for 32 years (1970-2002) with medical interviews and 
measurements at the ages of 50, 60, 70, and 77 (Table 11). Information on the 
cardiovascular events of the participants was obtained from the National Hospital 
Discharge Register and the National Causes of Death Register.  
 
Table 11. The ULSAM follow-up cohort. 
 Survey I Survey II Survey III Survey IV End of 
follow-up 
Age 50 years 60 years 70 years 77 years  
Year of survey 1970-1973 1981-1984 1991-1995 1997 2002 
Number of 
participants 
examined 
2,322 1,860 1,221 839  
      
CVD events a 14 134 373 518 701 
MetS ATPIII b 452 662 878 969 - 
Total mortality - 98 442 748 1,078 
Ineligible - 94 219 176 - 
      
Measurements Questionnaire Questionnaire Questionnaire Questionnaire  
 Cholesterols c Cholesterols c Cholesterols c Cholesterols c  
 Blood pressure Blood pressure Blood pressure Blood pressure  
 Fasting glucose Fasting glucose Fasting glucose Fasting glucose  
 BMI BMI, waist 
grid 
BMI, waist 
grid 
Waist grid  
 ApoA-1, 
ApoB-100 
IVGTT ApoA-1, 
ApoB-100 
  
 IVGTT  Insulin clamp   
   Blood samples 
for DNA 
  
Numbers for CVD events, metabolic syndrome (MetS), and mortality are cumulative from the baseline. 
a A coronary event or ischemic stroke during follow-up. Nine people with baseline CVD (50 years of age) had 
another event during follow-up. 
b ATP III criteria (male-specific) used. Individuals with missing values excluded at each time point. 
c Cholesterols: Total cholesterol, high-density lipoprotein cholesterol, triglycerides 
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4.2.2 The Helsinki Sudden Death Study sample (II) 
Finnish middle-aged men who died suddenly outside of hospital in the Helsinki City 
area during 1981-1982 and 1991-1992 were included in the HSDS study (Table 10). 
Areas of different types of atherosclerotic lesions and coronary narrowing were 
measured in medicolegal autopsy of the study subjects. These measurements defined 
fatty streaks (areas stained red with Sudan IV and unaffected with other types of 
changes), fibrotic lesions (elevated plaque areas that exhibited no ulceration or 
thrombosis), complicated lesions (plaque areas with ulceration or thrombosis), and 
advanced lesion areas (formed by combining elevated plaque areas and complicated 
lesion areas). Calcification of the arteries was measured by x-rays. 
4.2.3 The FINRISK study samples (III) 
From the original FINRISK study samples, a case-cohort subset was included in this 
study of the USF1 gene (Table 10, Figure 9, and Figure 10). In 1992 the original 
FINRISK -92 study invited 4,000 men and 4,000 women from 4 regions of Finland 
(Figure 9 and Figure 10) to a physical baseline examination. FINRISK -97 study 
invited 6,000 men and 5,500 women from 5 regions 5 years later (Figure 9 and 
Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. FINRISK study areas. 
1: Turku and Loimaa district
2: Helsinki and Vantaa
3: Kuopio Province
4: North Karelia
5: Oulu Province
1 2
3 4
5
FINRISK 1992 and 1997 cohort
FINRISK 1997 cohort
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After the follow-up periods (FINRISK -92 ten years, FINRISK -97 seven years) 
participants with incident coronary heart disease or stroke during the follow-up, and 
participants with a venous thromboembolic event or death during follow-up, were 
selected for genotyping in this study (Figure 10). A random subcohort of the original 
follow-up samples was also genotyped (Figure 10). In addition, participants with 
CVD at the baseline of the study were selected for genotyping. Information on the 
events or death during the follow-up periods was obtained from specific myocardial 
infarction and stroke registers (FINAMI and FINSTROKE) and from the National 
Hospital Discharge Register and the National Causes of Death Register.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The FINRISK follow-up cohort. Number of participants at different 
stages of the follow-up. At the end of the follow-up, cases and random subcohorts 
were selected for genotyping and analyses. M=males, F=females. 
FINRISK 1992 FINRISK 1997 FINRISK 1997
65-74 year olds
Selected to cohort
Examined at baseline
10 years of follow-up
(1992-2001)
7 years of follow-up
(1997-2003)
Selection of the random subcohort
Death
8,000
(M 4,000, F 4,000)
5,999
(M 2,833, F 3,166)
10,000
(M 5,000, F 5,000)
1,500
(M 1,000, F 500)
Coronary heart
disease Ischemic stroke
Death
Subcohort Subcohort
7,043
(M 3,365, F 3,678)
1,098
(M 727, F 371)
196
(M 143, F 53)
68
(M 35, F 33)
282
(M 188, F 94)
127
(M 97, F 30)
78
(M 59, F 19)
35
(M 25, F 10)
45
(M 34, F 11)
155
(M 106, F 49)
173
(M 136, F 37)
400
(M 286, F 114)
386
(M 304, F 82)
Coronary heart disease Ischemic stroke
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4.2.4 Whole genome amplified FINRISK samples (IV) 
FINRISK -92 DNA samples with an available DNA amount less than or equal to 7.5 
μg were selected for the WGA study. A control DNA sample set comprised 36 
high-yield samples that are regularly used as laboratory controls in our laboratory. 
4.3 Laboratory methods 
4.3.1 DNA extraction 
DNA of ULSAM (I) participants was isolated with a standard salting-out method 
from EDTA blood samples drawn at 70 years. In addition, for some samples DNA 
was extracted from paraffin-embedded tissues with K digestion and QIAamp 
minikits (Qiagen Inc., CA, USA). In the HSDS (II) 1981-1982 series, DNA was 
extracted from paraffin-embedded samples of cardiac muscle with a modification of 
the method by Isola and colleagues (Isola et al. 1994). In the HSDS (II) 1991-1992 
series, a standard phenol-chloroform method (Vandenplas et al. 1984) was used to 
extract DNA from frozen (-70°C) cardiac samples. The DNA of each FINRISK (III, 
IV) participant was extracted from 10 ml of EDTA-treated whole-blood samples 
using a standard phenol-chloroform method (Vandenplas et al. 1984) or salt 
precipitation. 
4.3.2 Marker selection and genotyping 
Genotyped USF1 polymorphisms with their minor allele frequencies are shown in 
Figure 11. 
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Figure 11. Minor allele frequencies of the genotyped USF1 SNPs. Minor allele 
frequencies are for individuals free of CVD. Only the SNPs tagging the three most 
common USF1 haplotypes were genotyped in the ULSAM (I) study (rs2774279, 
rs2516839, rs2073658). SNPs genotyped in the WGA study (IV) are indicated with 
an asterisk. The minor allele of each SNP is underlined. Genes ARHGAP30 and 
F11R are only partially shown in the figure, and the distance between the genes is 
out of proportion. The distance from rs2774279 to rs10908821 is 9.02 kb. 
Tel=telomere, cen=centromere. 
 
SNP selection was based on the haplotype structure of the USF1 region and all 
common (frequency >5%) LD bins listed in the SeattleSNPs Variation Discovery 
Resource were covered with the six selected SNPs. 
The genotyping methods included a single-base primer extension assay with 
fluorescence polarization detection (I), Sequenom’s MALDI-TOF mass 
spectrometry (II-IV), and allele-specific primer extension on microarrays (II-IV). 
4.3.3 Whole genome amplification  
FINRISK samples with a low DNA yield were amplified for the whole genome with 
GenomePhi DNA amplification kit (Amersham Biosciences, Piscataway, NJ) and 
cleaned by Spin column chromatography using MicroSpin G-50 Columns 
(Amersham Biosciences). FINRISK WGA DNA samples were genotyped as 
genomic DNA samples in the study III and 59 WGA samples were included in the 
study of reproducibility and accuracy of the genotyping (IV) (Figure 12).  
5’ 3’
rs2774279*
A/G
0.33
0.26
0.28
rs1556259
A/G
-
0.15
0.14
rs2516839*
C/T
0.38
0.40
0.38
rs2774276
C/G
-
0.26
0.25
rs2073658*
C/T
0.30
0.33
0.33
rs10908821*
C/G
-
0.15
0.15
USF1 F11RARHGAP30
ULSAM (I)
HSDS (II)
FINRISK (III)
tel cen
3’ 5’
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Figure 12. Study design of the whole genome amplification of DNA samples with 
low DNA yield. From the FINRISK study cohort, 59 low-yield DNA samples were 
amplified with whole genome amplification (WGA) in two replicates. Forty of the 
samples were also available for direct genotyping of the genomic DNA. These 
samples were genotyped with 24 SNPs and the genotypes were compared. In 
addition, 16 of the SNPs were genotyped using pooled samples of the WGA 
replicates. 
4.4 Statistical methods 
Haplotypes of the USF1 region were estimated with Haploview 3.2 using default 
settings (Barrett et al. 2005) and the haplotype carrier status of the study subjects 
was determined from the haplotype-tagging properties of the SNP alleles (I-III).  
Pearson’s 2-statistic was used to compare the allele frequencies between cases and 
non-cases (I, III).  
Time-to-event analyses were performed with the Cox proportional hazards 
regression model (I, III). In the FINRISK analyses (III), a weighted Cox 
proportional hazards model, modified to account for the case-cohort sampling 
design, was used for risk analyses with the variance correction based on the 
published literature using SAS PHREG procedure (Prentice 1986; Lin and Wei 
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1989; Barlow 1994). Age represented the time measure in the models, which were 
adjusted for sex, hypertension, smoking, diabetes, total cholesterol to HDL ratio, and 
BMI. Individuals with prevalent CVD at the baseline were excluded from analyses 
of incident CVD (I, III). FINRISK analyses (III) were stratified for eastern and 
western Finland, and the FINRISK cohort was used as a covariate. In the analyses, 
the SNP genotypes were analyzed as two groups; the carriers of the minor alleles vs. 
the non-carriers of the minor alleles (I, III). In the FINRISK analyses, a grouping of 
carriers of the major alleles vs. non-carriers of the major alleles was also used.  
Associations between USF1 alleles and several quantitative variables were tested 
with general linear models (PROC GLM of SAS for Windows V8/9.1) (I, III) or 
with mixed longitudinal models (PROC MIXED of SAS for Windows V8) (I). The 
ULSAM dataset (I) was analyzed in groups comprising the whole population cohort, 
CVD patients, MetS patients, and healthy subjects free of CVD and MetS. In 
FINRISK (III), men and women were analyzed independently in the groups of 
incident CVD cases and in subcohort members free of CVD. Outliers (+/- 4SD) 
were removed before analysis, and HDL (I, III), triglyceride (I, III), LDL (I), TGs 
(I), BMI (I), waist grid (I), and systolic and diastolic blood pressures (I) were 
log-transformed to correct them to be normally distributed. Lp(a), fasting glucose, 
HOMA -cell, and the clamp variables were corrected with rank procedure (I). 
Study subjects taking medication for their lipid levels, hypertension, or diabetes, 
were excluded from the analyses for these variables. To evaluate the significance of 
our findings, we permuted the genotype while retaining the phenotype data within 
sex/cohort groups, and repeated the same analyses that were performed with the 
actual dataset, recording the minimum p-value observed. We repeated this procedure 
1,000 times and took the fifth percentile of these minimum p-values as the new 
multiple-testing corrected threshold for the p-values obtained with the original data. 
Logistic regression models (PROC LOGISTIC of SAS for Windows V8/9.1) were 
used to test association of the USF1 with atherosclerotic variables or sudden cardiac 
death in the HSDS study (II). Genotype-based and haplotype-based analyses were 
carried out on a combined data set of the HSDS 1981-2 series and 1991-2 series, and 
also on both separately, to establish how the associations observed in the combined 
data replicate in the two series. The genotypes were analyzed under a codominant 
model and in the haplotype analysis haplotype carriers were compared against 
non-carriers. Due to the skewed distribution of the quantitative measurements of 
atherosclerotic lesions, we modeled the risk of atherosclerosis with the multivariable 
ordinal regression model (cumulative logit model) where quartiles of the 
atherosclerotic variable were the ordinal outcome. In these analyses, BMI, age, and 
HSDS series were covariates in the models. The risk of sudden cardiac death was 
analyzed as a binary outcome in a standard logistic regression model, where age and 
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HSDS series were covariates. Statistical significance in the analyses was set at 0.05. 
The p-values were adjusted for multiple comparisons with a false discovery rate 
(FDR) implemented in the SAS MULTTEST procedure. Each adjustment procedure 
included one SNP or a haplotype, and all tested phenotypes. 
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5 RESULTS AND DISCUSSION 
5.1 Genetic variants of USF1 and risk factors for cardiovascular 
disease (I, III) 
At the initiation of our work, the association between USF1 and FCHL had just been 
described in exceptional Finnish dyslipidemic families (Pajukanta et al. 2004). Our 
aim was to examine whether variation at the USF1 locus would be of more general 
importance for lipid phenotypes and other risk factors for cardiovascular disease at 
the population level. This was achieved through examination of USF1 variants in 
two large prospective population cohorts.  
The follow-up period of the ULSAM (I) population cohort included four medical 
examinations, where measurements for serum lipids, blood pressure, and body 
anthropometrics were made (Table 12). 
 
Table 12. Characteristics of the ULSAM (I) cohort. 
 
Age 50 
(n=2,322) 
Age 60 
(n=1,860) 
Age 70 
(n=1,221) 
Age 77 
(n=839) 
 Mean (SD) 
Total cholesterol (mmol/l)a 6.87 (1.31) 6.31 (1.10) 5.82 (1.00) 5.48 (0.96) 
LDL cholesterol (mmol/l)a 5.26 (1.24) 4.28 (0.96) 3.90 (0.89) 3.56 (0.84) 
Triglycerides (mmol/l)a 1.93 (1.22) 1.85 (1.01) 1.45 (0.78) 1.36 (0.68) 
HDL cholesterol (mmol/l)a 1.36 (0.40) 1.19 (0.34) 1.28 (0.35) 1.32 (0.33) 
Blood pressure (mmHg)b 132/83 (17/11) 140/86 (19/9) 144/82 (17/9) 149/80 (21/10) 
BMI (kg/m2) 25.03 (3.22) 25.49 (3.28) 26.30 (3.43) - 
Waist circumference (cm) 87.86 (8.84) 90.99 (10.03) 94.82 (9.65) 95.60 (9.86) 
ApoB-100 (g/l)a 1.24 (0.28) - 1.03 (0.23) - 
ApoA-I (g/l)a 1.43 (0.25) - 1.28 (0.23) - 
Lp(a) (U/l)a 245.9 (305.2) - 305.3 (360.4) - 
Fasting glucose (mmol/l) 4.96 (0.61) 4.81 (0.58) 5.36 (0.58) 5.48 (0.58) 
a Individuals with lipid lowering medication removed (n=166)  
b Individuals using antihypertensive medication removed (n=466) 
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Variation at the USF1 locus associated with longitudinally measured BMI, total 
cholesterol, HDL and LDL, either among participants with metabolic syndrome or 
with CVD (Table 13). Associations among individuals free of these conditions were, 
however, absent (Table 13). 
 
Table 13. Association (p-values) of the USF1 SNPs with longitudinally measured 
cardiovascular risk factors 
Variable     rs2073658                     rs2774279                   rs2516839 
 MetSa CVDb Healthyc MetSa CVDb Healthyc MetSa CVDb Healthyc 
BMI                0.05(+)       0.05(+)    
Waist                   
TC              0.01(-)d             
LDL            0.02 (-)               
HDL              0.02(+)        
A - indicates that the minor allele associates with an unfavorable profile of the variable, a + indicates 
association of the minor allele with a favorable profile.  
a Metabolic syndrome by the ATP III criteria 
b CVD: Individuals with cardiovascular events 
c Individuals with no CVD events or metabolic syndrome 
d Significant finding after multiple testing correction as 5th percentile of 1,000 permutations 
 
In addition, associations between SNP rs2073658 and longitudinally measured 
lipoproteins related to FCHL were observed; minor allele of the SNP associated with 
higher ApoB-100 values among participants with MetS (p=0.01), and with higher Lp(a) 
values among CVD cases (p=0.02) and healthy individuals (p=0.03). Only the ApoB-
100 association, however, remained significant after correction for multiple testing. 
Minor allele of SNP rs2774279 associated with lower fasting glucose levels among 
participants with CVD (p=0.01, significant after correction for multiple testing).  
A cross-sectional analysis of the data at 70 years, which compared SNP associations 
among four different clinical definitions of MetS, further supported a protective role 
of the minor allele (A) of rs2774279; The minor allele carriers had higher mean 
HDL (p=0.02 – p=0.06) and lower mean Lp(a) (p=0.005 – p=0.07) values compared 
to the non-carriers of the allele, independently of the MetS definition used. 
Furthermore, the minor allele frequency of rs2774279 was lower among those with 
MetS diagnosed at one or more surveys when compared to healthy individuals (0.29 
vs. 0.33, p<0.01, significant after adjusting the significance level for multiple tests). 
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In the FINRISK (III) studies, lipid and body composition measurements of the 
follow-up cohorts were conducted at the baseline of the study (Table 14). 
 
Table 14. Baseline characteristics of FINRISK (III) cardiovascular cases and the 
subcohort 
 FR92+FR97 Males FR92+FR97 Females 
Characteristic CVD casesa Subcohortb CVD casesa Subcohortb 
     
 Mean (SD) 
Number of subjects 374 451 154 175 
Total cholesterol (mmol/l)c 6.02 (1.09) 5.76 (0.99) 6.06 (1.15) 5.98 (1.03) 
HDL cholesterol (mmol/l)c 1.17 (0.30) 1.27 (0.34) 1.37 (0.38) 1.56 (0.36) 
Non-HDL cholesterolc 4.85 (1.09) 4.49 (1.00) 4.68 (1.19) 4.41 (1.03) 
Triglyceridesc 2.00 (1.14) 1.74 (1.02) 1.82 (1.05) 1.41 (0.81) 
Waist to hip ratio 0.97 (0.06) 0.95 (0.06) 0.84 (0.07) 0.81 (0.06) 
Body mass index (kg/m2) 28.6 (3.6) 27.5 (3.9) 29.3 (4.9) 27.3 (4.6) 
a Incident CVD cases (includes incident CHD cases and incident ischemic stroke cases) 
b Subcohort members without CVD at baseline or during the follow up 
c Persons with lipid lowering medication at baseline (n=44) were excluded from calculations 
 
Although some suggestive associations between USF1 and the measurements were 
observed in the FINRISK (III) subcohort (Table 15), only one remained significant 
after permutation correction for multiple testing; the G-allele of rs2774276 was 
associated with a higher waist-to-hip ratio among men. Interestingly several 
associations were observed among participants with CVD (Table 15). Four USF1 
SNPs associated with total cholesterol values, and three SNPs with non-HDL 
cholesterol values, especially among men. SNP rs2516839 associated with 
non-HDL cholesterol and total cholesterol values both among men and women, and 
also with BMI among women (Table 15). 
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Table 15. Association (p-values) between USF1 SNP alleles and lipids, BMI, and 
waist-to-hip ratio in FINRISK (III) CVD case men and women   
Marker 
A
llelea 
G
roup 
TC 
(mmol/l) 
HDL 
(mmol/l) 
Non-HDL 
cholesterol 
TG 
(mmol/l) 
BMI  
(kg/m2) 
Waist-
To-Hip 
ratio 
   
      
rs10908821 G M      S 
  F       
rs2073658 C M 0.02(-)  0.03(-)    
  F    0.03(-)   
 T M 0.03(+)  0.02(+) 0.04(+)   
  F  S    S 
rs2774276 C M 0.01(+)  0.004(+)b    
  F       
 G M      S 
  F       
rs2516839 C M 0.001(-)b  0.001(-)b   S 
  F 0.02(-)  0.04(-)  0.006(-)b  
 T M 0.04(+)  0.04(+)    
  F       
rs1556259 G M 0.03(-)      
  F       
rs2774279 A M       
  F       
 G M S  S    
  F  S     
A - indicates that allele associates with an unfavorable profile of the variable, a + indicates association with a 
favorable profile. M=males, F=females, S=suggestive association in the subcohort 
a Persons carrying the allele are pooled together and analyzed against non-carriers 
b p-value less than the critical value corrected for multiple testing 
 
Several studies in dyslipidemic families have demonstrated linkage or association 
between USF1 gene and FCHL (Pajukanta et al. 2004; Coon et al. 2005; Huertas-
Vazquez et al. 2005; Lee et al. 2007), a complex dyslipidemia often implicated in 
patients with premature coronary heart disease (Genest et al. 1992). Our data 
suggests that variation at the USF1 locus may also contribute to lipid phenotypes 
and other cardiovascular risk factors more widely at the population level.  
The FCHL phenotype comprises various lipid component traits and several studies 
have assessed them in the presence of USF1 variation (Figure 13, Table 16, and 
Table 17). Many of those studies have included polymorphisms rs2073658 and 
rs3737787, two highly correlated SNPs with the strongest associations to FCHL and 
triglycerides in the first FCHL study by Pajukanta and colleagues (Pajukanta et al. 
2004).  In addition to FCHL, the common allele of the two SNPs has associated with 
higher levels of apolipoproteins and free fatty acids (Table 16). Furthermore, 
carriers of the common alleles of these risk SNPs have shown higher levels of serum 
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total cholesterol, triglycerides and LDL (Table 17). While many studies have 
reported significant associations with these lipid phenotypes, replication has at times 
been LDL (Table 17). While (Gibson et al. 2005; Hoffstedt et al. 2005; Ng et al. 
2005; Zeggini et al. 2006; Kantartzis et al. 2007).  
Most of the USF1 studies have ascertained their study samples with specific criteria, 
such as presence of FCHL, CVD, diabetes, or obesity (Table 16 and Table 17). Our 
samples were Finnish (FINRISK, III) and Swedish (ULSAM, I) prospective 
population cohorts. In the ULSAM (I) cohort, longitudinal measurements of serum 
lipids and other cardiovascular risk factors were examined in relation to USF1 
variation. Contradictory to studies where the common allele (C) of rs2073658 
associated with a more unfavorable risk profile, in the ULSAM (I) the minor allele 
(T) of rs2073658 associated with a higher total and LDL cholesterol, apolipoprotein 
B-100, and lipoprotein-a concentrations. The risk trend prevailed throughout the 
follow-up time of three decades. Interestingly, the ULSAM (I) associations were 
almost solely present among participants with MetS or CVD, suggesting that a 
certain pathophysiological state is required for the USF1 gene effect to emerge. This 
was further indicated in the FINRISK (III) study sample where the common allele of 
rs2073658, and other SNPs, contributed to higher lipids in CVD cases, but not in the 
subcohort (Table 17). 
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In addition to the involvement of USF1 in lipid phenotypes, our population cohorts 
also revealed the association of USF1 SNPs with some other important CVD risk 
factors (Table 18). Both in FINRISK (III) and in ULSAM (I), the SNP rs2516839 
associated with the BMI or waist-to-hip ratio (Table 18). The trend of the effect of 
the rare allele of rs2516839 in ULSAM (III) was, however, discordant to other 
studies (Table 18). Rs2774279 also associated with BMI in the ULSAM (I) study 
sample of Swedish men. This association was also present in subsequent analyses of 
the FINRISK (III) cohort where SNP associations were analyzed under a 
codominant model instead of the dominant and recessive models (Kristiansson 
2007) (Table 18). Furthermore, the association of rs2774279 with BMI displayed a 
sex-specific effect, as the rare allele correlated with a favorable risk profile among 
men and an unfavorable one among women (Table 18) (Kristiansson 2007). While 
the possibility of a spurious finding exists, these types of discordances, which have 
also been reported in other studies (Lee et al. 2007; Reiner et al. 2007), may reflect 
the complicated, interacting nature of the USF1 effect. Suggestive evidence of gene-
sex, gene-gene, gene-age, and other interactions exists for USF1 (Putt et al. 2004; 
Coon et al. 2005; Choquette et al. 2007; Kantartzis et al. 2007; Lee et al. 2007; 
Reiner et al. 2007). Reports of associations specific to groups of study subjects with 
certain pathophysiological state, such as obesity, MetS, or CVD, further add to the 
complexity. 
We observed USF1 to associate with MetS in the ULSAM (I) cohort, an association 
also suggested in other studies (Table 18). Although we, in concordance to some 
other studies (Table 18), also detected USF1 to associate with fasting glucose 
values, the contribution of USF1 to type 2 diabetes remains unclear. Initial 
associations (Ng et al. 2005; Zeggini et al. 2006) have failed to be replicated in other 
populations or subsequent studies (Gibson et al. 2005; Ng et al. 2005; Zeggini et al. 
2006; Reiner et al. 2007).  
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5.2 USF1 and atherosclerosis (II) 
Cholesterol, triglycerides, and other atherogenic components that circulate in the 
blood or are present in arterial vessel walls, crucially contribute to atherosclerosis 
and its complications, such as myocardial infarction and stroke. USF1 associated 
with risk factors for cardiovascular disease in our studies, as well as in other studies. 
We thus sought to relate variation at the gene locus to the extent and severity of 
atherosclerosis at the level of the vessel walls of the coronary arteries and abdominal 
aorta. To accomplish this, we studied the vessel walls of 700 middle-aged men from 
the HSDS (II) study where medicolegal autopsies provided detailed data on several 
types of atherosclerotic changes on the arteries of the study subjects (Table 19). Two 
HSDS study sample series collected in 1981-82 (n=400) and 1991-92 (n=300) were 
analyzed. 
 
Table 19. Characteristics of the Helsinki Sudden Death Study (HSDS) (II) sample 
 1981-82 series    (n=400) 
1991-92 series     
(n=300) 
Age , years±SD 53.8±9.5 52.1±9.6 
Body mass index, kg/m2±SD 24.2±4.6 25.1±5.0 
   
Cause of death, n (%)   
     Sudden cardiac death 150 (37.5) 80 (27) 
     Other disease 98 (24.5) 100 (33) 
     Non-natural deaths (accidents, suicides) 152 (38) 120 (40) 
   
Presence of coronary atherosclerotic changes, n (%)   
     Fatty streaks 381 (95) 282 (94) 
     Fibrous lesions  346 (87) 232 (77) 
     Complicated lesions 195 (49) 101 (34) 
     Calcified lesions 317 (79) 205 (68) 
> 50% coronary narrowing in more than one coronary artery 120 (30) 38 (17) 
 
Genotype and haplotype analyses of USF1 in the HSDS (II) study samples revealed 
a single SNP, which consistently associated with several kinds of atherosclerotic 
lesions in the arteries of the HSDS study subjects. Study subjects with two copies of 
the rs2516839 T-allele had mainly larger areas of atherosclerotic changes than those 
with only one copy of the T-allele. Conversely, the CC genotype associated with a 
protective effect (Table 20). The risk effect of the T-allele on advanced 
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atherosclerosis and calcification was present both in the coronary arteries and in the 
abdominal aorta of the study subjects (Table 20). 
Table 20. Association between USF1 rs2516839 genotype and atherosclerosis in 
coronary arteries and abdominal aorta 
 Percentage area of atherosclerosis lesion type, mean±SD TT vs. CC 
 CC (n=100) CT (n=304) TT (n=253) 
OR 
(95% CI)a 
p-valueb 
Coronary arteries      
Fatty streaks 8.82±7.04 8.41±7.40 8.17±6.95 0.79 (0.52-1.21) 0.28 (0.29) 
Fibrous lesions  5.73±5.34 7.67±8.91 7.89±7.22 1.65 (1.08-2.52) 0.02 (0.05) 
Complicated lesions 1.33±2.81 2.86±7.30 2.99±5.43 1.82 (1.11-2.98) 0.02 (0.05) 
Total lesion area 14.40±8.78 17.04±13.12 16.81±11.22 1.30 (0.85-1.99) 0.23 (0.26) 
Advanced 
atherosclerosisc 
6.78±6.29 9.81±11.64 9.94±8.86 1.72 (1.12-2.64) 0.01 (0.04) 
Proportion of advanced 
lesion area out of the 
total lesion area 
0.50±0.32 0.57±0.31 0.60±0.30 1.91 (1.24-2.94) 0.003 (0.02) 
Calcified lesions 2.36±3.69 4.03±6.41 5.40±7.24 2.80 (1.80-4.35) <0.001 (<0.001) 
      
Abdominal aorta      
Fatty streaks 11.15±9.12 14.27±10.91 12.95±10.26 1.50 (0.98-2.28) 0.06 (0.09) 
Fibrous lesions  5.56±5.33 6.48±6.19 7.12±6.51 1.44 (0.94-2.20) 0.09 (0.11) 
Complicated lesions 5.70±10.71 6.37±9.27 7.02±10.52 1.49 (0.95-2.34) 0.08 (0.10) 
Total lesion area 22.40±16.60 26.97±16.96 26.88±17.29 1.59 (1.04-2.43) 0.03 (0.06) 
Advanced 
atherosclerosisc 
11.25±13.16 12.86±12.80 14.17±13.57 1.65 (1.07-2.56) 0.02 (0.05) 
Proportion of advanced 
lesion area out of the 
total lesion area 
0.42±0.26 0.43±0.27 0.47±0.27 1.26 (0.82-1.94) 0.29 (0.29) 
Calcified lesions 3.29±5.20 3.85±6.12 4.34±6.13 1.60 (1.03-2.48) 0.04 (0.06) 
SD: Standard deviation; OR: Odds ratio; CI: Confidence interval 
a Odds ratio and 95% confidence interval from ordinal logistic regression analysis. The variables were 
analyzed as quartiles with an ordinal regression model due to their skewed distribution. See publication II. 
b p-value adjusted for multiple comparisons in parenthesis 
c Plaque area covered either by fibrotic or complicated lesion    
 
The effect of rs2516839 was observed independently in the two HSDS (II) autopsy 
series: Carriers of two risk alleles were 2.4 times as likely to have more severely 
calcified coronary arteries in the 1981-82 series (OR 2.39, 95% CI 1.30-4.40) and 
3.2 times as likely in the 1991-92 series (OR 3.20, 95% CI 1.68-6.09), than 
non-carriers of the allele (Figure 14). 
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Figure 14. Association of rs2516839 with calcification of the arteries in the two 
HSDS (II) autopsy series. The figure shows odds ratios and their confidence 
intervals from the ordinal logistic regression analysis which compared the CT and 
TT genotypes to the CC genotype. Advanced atherosclerosis = plaque area covered 
either by fibrotic or complicated lesion. a p<0.05, b p<0.01, c p<0.001, d Multiple 
testing adjusted p<0.05. 
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In addition to rs2516839, SNPs rs2073658 and rs2774279 showed statistically 
significant association with the amount of calcification in the coronary arteries. 
These associations were, however, non-significant in regression models adjusted for 
SNP rs2516839. The associations obtained from the analyses of rs2516839 were 
also stronger than the few suggestive associations seen in haplotype analyses. 
We and others have presented data on the effect of USF1 on several cardiovascular 
risk factors, most prominently on lipid phenotypes (Table 16 and Table 17). These 
lipids participate in atherogenic processes leading to the development of plaques in 
the arteries and thus we hypothesized that genetic variation at the USF1 locus could 
associate with severity of coronary atherosclerosis. We obtained evidence to support 
our hypothesis by studying coronary arteries and abdominal aortas of Finnish 
middle-aged men of the Helsinki Sudden Death Study (II).  
Rs2516839 consistently associated with several kinds of atherosclerotic lesions in 
the arteries of the HSDS (II) study subjects (Table 20 and Figure 14) and the 
strongest association involved coronary calcification. A study by Reiner and 
colleagues also identified a link between USF1 and coronary artery calcium (CAC): 
the rare allele of rs3737787 was associated with a decreased risk of CAC in 
otherwise healthy young adults (Reiner et al. 2007). Their study included a SNP 
highly correlated with our rs2516839, but they reported no association between 
CAC and that particular SNP. In another study, evidence of rs3737787 contributing 
to coronary stenosis in a prospective clinical cohort was absent (Lee et al. 2007).  
Rs2516839 was undeniably the most significantly associated USF1 polymorphism in 
our autopsy study sample, evidenced by the non-significance of the other SNPs in an 
analysis model where rs2516839 was present. Although this could explain the lack 
of association in the study of Lee and colleagues where only rs3737787 was 
investigated (Lee et al. 2007), it is contradictory to the study of Reiner and 
colleagues (Reiner et al. 2007). While several functional alleles at the USF1 locus 
could exist, their identification is obscured by the high LD present in the region 
(Pajukanta et al. 2004; Reiner et al. 2007). Reiner and colleagues examined the 
nature of this LD and concluded that in their study the true susceptibility effect on 
mortality may be attributable, at least in part, to neighboring polymorphisms in other 
genes (Reiner et al. 2007). For atherosclerosis this hypothesis is particularly 
interesting: next to USF1 resides a 42 kb gene encoding F11-receptor (F11R), which 
is expressed on the surface of platelets and localized within tight junctions of 
endothelial cells (EC). The gene was recently implicated in atherothrombosis in a 
study where the overexpression of F11R was present in atherosclerotic plaques 
(Babinska et al. 2002; Babinska et al. 2007). 
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Still, as USF1 has a role in the regulation of several genes encoding components of lipid 
and inflammation pathways, its contribution to atherosclerosis remains plausible.  
5.3 USF1, sudden cardiac death, and the incidence and prevalence 
of cardiovascular disease (I, II, III) 
After finding evidence on the effect of the USF1 locus on levels of CVD risk factors 
and atherosclerosis, we hypothesized that this effect might be observed as an 
occurrence of acute CVD events and death.  
In the HSDS (II) study sample where USF1 SNP rs2516839 associated with 
atherosclerosis at the vessel wall level, the risk allele also associated with sudden 
cardiac death. The carriers of a TT genotype had a 2-fold risk for SCD compared to 
that of the carriers of the protective CC genotype (TT; OR 2.10, 95% CI 1.17-3.75, 
p=0.01, and CT; OR 1.92, 95% CI 1.09-3.39, p=0.02). Part, but not all, of the 
increased risk of SCD associated with the SNP was due to the SNP’s contribution to 
the development of severe coronary artery disease characterized by coronary 
calcification.  
Among the FINRISK (III) female, but not male, study subjects, carriers of the minor 
allele (A) of rs2774279 were at a lower risk of belonging to the group of study 
subjects with a baseline history of a cardiovascular event (AA vs. GG: OR 0.51, 
95% CI 0.26–0.99 and AG vs. GG: OR 0.71, 95% CI 0.51–1.00, p=0.05) 
(Kristiansson 2007). In addition, female carriers of the minor allele of rs2073658 (T) 
had a higher risk of a baseline CVD history (TT vs. CC: OR 2.01, 95% CI 1.06–3.83 
and CT vs. TT: OR 1.42, 95% CI 1.03–1.96, p=0.03) (Kristiansson 2007). 
A relation between variation at the USF1 locus and prevalent CVD was thus suggested 
by our results and we further extended our analyses of USF1 to incidence of CVD 
with our prospectively followed population cohorts. Among the FINRISK (III) 
women, the two USF1 SNPs that were associated with prevalent CVD also associated 
with the incidence of CVD during the follow-up period (Figure 15). Interestingly, 
these SNPs also associated with mortality; carriers of the rs2073658 T-allele and 
carriers of the rs2774279 G-allele had an increased risk of all-cause mortality 
compared to non-carriers of the allele (rs2073658 T-allele: HR 2.52, 95% CI 1.46–
4.35, p=0.0009; rs2774279 G-allele: HR 4.43, 95% CI 1.58–12.40, p=0.005). 
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Figure 15. USF1 and incidence of cardiovascular event among FINRISK (III) females. 
a p<0.05, HR=hazard ratio, CI=confidence interval, mm=homozygote of the minor 
allele, mM=heterozygote, MM=homozygote of the major allele. A codominant 
model for the genotypic effect was used in the analysis. 
 
Among FINRISK (III) men, association between USF1 and CVD was absent. When 
a possibly more genetically predisposed group of FINRISK men was examined, 
however, a suggestive association between the SNP rs2516839 and incident CVD 
was observed. Among those men, whose first degree relatives had a history of CVD, 
carriers of the minor allele of rs2516839 were at a lower risk of CVD during the 
follow-up (CC vs. TT: HR 0.52, 95% CI 0.28–0.96, p=0.04 and CT vs. TT: HR 
0.63, 95% CI 0.43–0.93, p=0.02) (Kristiansson 2007).  
Analyses of the ULSAM (I) study sample men also failed to show any significant 
association between USF1 variation and incidence of CVD. 
Our data on the population cohorts supported the role of USF1 alleles in lipid 
metabolism, atherosclerosis, and also contributing in a few other cardiovascular risk 
factors. In addition we obtained evidence for how the risk increasing effects of 
USF1 alleles eventually play a part in sudden cardiac death or in incidence of CVD.   
In the HSDS (II) study sample the atherosclerosis-associated risk allele also 
associated with sudden cardiac death among the men. The same allele associated 
with incidence of CVD among FINRISK (III) men, but only after a prospectively 
more genetically predisposed group of men was studied. USF1 alleles failed to show 
any differential effect on the risk of CVD among ULSAM (I) men.  
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The FINRISK (III) study sample also included women, and among them the relation 
between USF1 alleles and CVD was more evident than among men. Two USF1 
polymorphisms associated with the incidence of CVD. Carriers of the A-allele of 
rs2774279 had a lower risk of CVD compared to the non-carriers of the allele. This 
protective effect of the allele was observed in both FINRISK cohorts (1992 and 
1997) and also among the baseline CVD cases. In addition, the T allele of 
rs2073658, associated with an increased risk for CVD, raising an interesting 
question of a possible sex-specificity of the USF1 effect, since the rare T allele has 
in many studies showed a protective effect especially among men (Table 17). 
Since most of the SNPs genotyped in the three study samples (I, II, III) each tag one 
USF1 haplotype, the SNP associations also represented haplotype associations. 
USF1 SNPs rs2073658, rs2516839, and rs2774279 were genotyped in all three 
study samples (I, II, and III), and their haplotype frequencies in those study samples 
were similar. The frequency of CCG was 38% (I), 39% (II), and 38% (III), 
frequency of CTA was 31% (I), 28% (II), and 29% (III), and frequency of TTG was 
31% (I), 33% (II), and 34% (III). These frequencies differed slightly from the 
haplotype estimates in the SeattleSNPs database (UW-FHCRC European SNPs, 47 
individuals) (SeattleSNPs, Variation Discovery Resource). SeattleSNP frequencies 
were 49% (CCG), 28% (CTA), and 17% (TTG). While SNPs rs2073658 and 
rs2774279, and thus haplotypes TTG and CTA, associated with CVD among 
FINRISK (III) women, it was SNP rs2516839, which associated with sudden 
cardiac death (II) and CVD (III) among men. Rs2516839 does not tag a single 
haplotype of USF1; instead, the risk-associated T-allele of the SNP is present in the 
haplotypes TTG and CTA. The haplotype CTA, which associated with a lower risk 
of CVD among women, thus presented a risk effect among men.   
Only a few other studies have examined USF1 on CVD (Lee et al. 2007; Reiner et 
al. 2007). Lee and colleagues examined rs3737787, a USF1 SNP in high correlation 
with rs2073658, and in concordance with our results found a significant sex-specific 
effect for the SNP alleles in lipid and BMI analyses (Lee et al. 2007) (Table 17 and 
Table 18). They failed, however, to observe any SNP association with MI or 
revascularization. Lack of association was also present in a study by Reiner and 
colleagues in which USF1 SNPs were analyzed in the incidence of CVD (Reiner et 
al. 2007). They, however, observed an association of USF1 rs3737787 with risk of 
all-cause mortality. The risk allele was the same as the CVD risk increasing allele in 
our FINRISK (III) women.  
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5.4 Whole genome amplification of the low DNA yield samples (IV) 
Some of the FINRISK (III) study samples we used had a low yield of DNA and 
were thus in danger of being excluded from the analyses. To avoid bias introduced 
by such exclusion, we amplified these DNA with whole genome amplification and 
evaluated whether the produced WGA genotypes were of good quality. 
When 59 low-yield DNA samples were whole-genome amplified in replicate and 
then genotyped with 24 SNPs (16 using the MassARRAY System and 8 using the 
microarray system), multiple genotype discrepancies were observed for 13 of the 
samples (Table 21). These discrepancies were detected both between WGA 
replicates and between a WGA product and genomic DNA, and most were due to a 
drop-out of one of the alleles in heterozygote WGA samples. More heterogeneous 
allele ratios were observed for these 13 samples, and allele calling problems, low 
signal intensities, and genotypes escaping from genotype clusters were common 
(Figure 16). Presence of genotype discrepancies did not correlate with the DNA 
amount or purity, although higher starting DNA concentrations for WGA 
amplification showed a higher genotype call rates.   
 
Table 21. Distribution of genotype discrepancies for the 13 problematic WGA samples  
 
Number of discrepant SNPs 
DNA 
concentration 
ng/μl 
Sample MassARRAY Microarray Total  
1 2  2 7 
2 2  2 11 
3  2 2 90 
4 1 2 3 31 
5 1 2 3 >0 
6 3 2 5 1 
7 5  5 13 
8 4 2 6 23 
9 6  6 30 
10 5 2 7 3 
11 7 1 8 18 
12 8 1 9 >0 
13 5 6 11 2 
Samples genotyped on a total of 24 SNPs. Genotype comparisons were made between WGA replicates of the 
same sample and genomic DNA. 
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Figure 16. An example of genotype clusters for WGA samples. Clusters are for 
microarray genotyping of the SNP rs2073658 for the 59 WGA DNA samples. The 
13 samples that show multiple genotype discrepancies are shown as black dots, 
while the 3 genotype clusters for the other 46 samples are shown as colored dots. 
Two dots are present for each sample since genotyping was done in duplicates. 
 
To evaluate whether pooling of the WGA replicates improves genotyping quality, 
equal amounts of the two WGA replicates for each sample were combined into one 
genotyping sample, which was then genotyped in duplicate with 16 SNPs using the 
MassARRAY System. The number of genotyping discrepancies was substantially 
reduced in the pooled samples (Table 22) and genotyping success rate was greater 
than 98%. 
 
Table 22. Comparison of WGA-genomic genotype discrepancies obtained for single 
WGA samples and pooled WGA samples 
 
 Number of samples 
with discrepancies 
Total number of 
discrepancies 
Number of unique 
discrepancies 
WGA single reactions 12 / 40 (30%) 97 / 3,148 (3.1%) 60 / 847 (7.1%) 
WGA pool 4 / 40 (10%) 12 / 1,125 (1.1%) 7 / 572 (1.2%) 
Genotypes for genomic DNA were only available for 40 out of 59 samples. 
Total number of discrepancies counted from 2 genotyping attempts for each replicate WGA-sample (i.e., a 
total of 4 genotyping attempts per sample for WGA single reactions, and 2 genotyping attempts for WGA 
pool), and one genotyping attempt for genomic DNA sample. 
Number of unique discrepancies: each SNP-sample comparison counted once. 
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In general, MPRCA-WGA appeared to be a feasible approach for amplification of 
low-yield DNA samples prior to genotyping in studies where sample exclusion on 
the basis of their DNA yield could introduce a bias into the analyses. We studied 
genotypes from genomic DNA samples and from two replicates of WGA samples 
produced by two genotyping platforms and twenty-four SNPs. For a majority of the 
59 samples studied, we obtained consistent WGA genotypes with high success rates. 
Thirteen samples, however, showed various genotype discrepancies. Furthermore, 
when we searched for characteristics common to these samples, such as correlation 
between the presence of discrepancies and DNA purity or concentration, and WGA 
DNA integrity or quantity, which could be used to distinguish them from other 
samples a priori, we failed to find any. 
Although the problematic samples giving genotype discrepancies could not be 
detected before genotyping with standard laboratory quality control methods, our 
results suggested that enhanced quality control at the time of the genotyping could 
identify such samples; these samples were often identified as having more 
heterogeneous allele ratios, allele calling problems, low signal intensities, and 
genotypes escaping from genotype clusters.  
Combining two WGA reactions into one pooled DNA sample for genotyping 
markedly reduced the number of discrepancies and samples showing them. This was 
in agreement with a previous study where the pooling of WGA products 
significantly reduced genotyping inconsistencies (Rook et al. 2004). Even after a 
pooling of WGA replicates, some inconsistency was observable in the genotypes 
produced, especially in the form of allele drop-outs. Thus in addition to pooling of 
WGA samples, increased quality control is required to complement for the higher 
rate of genotyping errors. 
5.5 General discussion on USF1 and the risk of CVD 
We obtained evidence that variation at the USF1 locus affects features of several 
CVD risk factors and contributes to atherosclerosis and to its symptoms; sudden 
cardiac death and prevalent and incident CVD. Our data enabled us to examine the 
effect of USF1 at the population level and in a prospective manner (I, III), instead of 
in special families or study samples ascertained with specific criteria. In addition, we 
could investigate the association of USF1 alleles with atherosclerosis using detailed 
data on different types of lesions at the vessel wall level (II).  
Our data and methods had some limitations; while in the ULSAM (I) study sample 
lipid and anthropometrics measurements were taken repeatedly during the follow-up 
period, in FINRISK (III) only one baseline measurement was obtained. Thus, some 
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FINRISK CVD events occurred as much as ten years after the baseline 
measurements and changes in the risk factors during that time could not be 
accounted for in the analyses models. Furthermore, plasma lipid levels were 
unavailable in the HSDS (II) study samples and so we could not directly relate 
atherosclerotic lesion areas to lipid levels. The FINRISK (III) analysis of a 
particularly interesting lipid measurement for USF1, triglycerides, was biased due to 
measurements taken after only 4 hours of fasting. This possibly explains the lack of 
association in our study compared to others. Another limitation could arise from our 
definition of CVD; the diagnosis of CVD is dependent on several factors, including 
the point in time when the patient seeks medical care where CVD can be diagnosed. 
Our study samples may include persons with severe atherosclerosis, who are still 
considered “healthy” because their disease is absent from the national registers. 
Furthermore, by combining ischemic strokes with coronary events, we are likely to 
gain power but also obtain a more heterogeneous end point for the analyses. The 
CVD analyses in ULSAM (I) may also have been affected by the late sampling of 
DNA at the age of 70, although we investigated this possibility and found no 
evidence of such bias. 
Although the chance of false positive findings cannot be ruled out, we took measures to 
minimize this in our analyses. Permutation or false discovery rates were applied to 
control for multiple testing. In FINRISK (III) and in HSDS (II) study samples we also 
had the opportunity to analyze USF1 in distinct sample sets to confirm the observed 
associations, and obtained consistent results with these analyses.  
Some of our results were consistent with those from other studies, while other data 
seemed ambiguous. Two SNPs in our data associated with lipid measurements, 
atherosclerosis, and with CVD endpoints; rs2073658 and rs2516839. The 
risk-increasing allele, however, was inconsistent between the study samples; while 
the common allele of rs2073658 associated with increased lipid levels in FINRISK 
(III) men, it lowered them in ULSAM (I) men, protected HSDS (II) men from 
atherosclerosis, and protected FINRISK (III) women from CVD and mortality. In 
FINRISK (III), the rare allele of rs2516839 increased BMI and cholesterol levels of 
both sexes, but protected HSDS (II) men from atherosclerosis and sudden cardiac 
death, and decreased BMI of ULSAM (I) men. Rare alleles of both SNPs have also 
shown both unfavorable and favorable effects in other studies, although the rare 
allele of rs2073658 has been protective in most studies (Table 16, Table 17, and 
Table 18). 
The apparent discrepancies in USF1 studies may be explained, for instance, with the 
existence of complicated interactions between USF1 and sex, age, other genes, and 
environmental factors. Sex-specific gene effects have been reported (Choquette et al. 
2007; Lee et al. 2007) and were also present in our study, although they could not be 
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examined in the ULSAM (I) or HSDS (II) samples, which comprised men only. 
Studies where any sex-specificity is absent also exist (Huertas-Vazquez et al. 2005; 
Reiner et al. 2007). These complicating factors could also in part explain the lack of 
signals at the USF1 locus in the genome-wide scans for regions contributing to 
cardiovascular outcomes (Pajukanta et al. 2000; Francke et al. 2001; Broeckel et al. 
2002; Harrap et al. 2002; Lange et al. 2002; Hauser et al. 2004; Helgadottir et al. 2004; 
Wang et al. 2004; Samani et al. 2005; Wang et al. 2005; Engert et al. 2007; Larson et 
al. 2007; Matarin et al. 2007; Nilsson-Ardnor et al. 2007; O'Donnell et al. 2007). 
Notably, in our FINRISK (III) and ULSAM (I) population cohort analyses, the SNP 
associations were almost exclusively present among CVD or MetS cases. This 
suggests that a certain pathophysiological state is required for the USF1 effect to 
become detectable. Other studies have also suggested this, and especially 
USF1-BMI interactions have been proposed (Putt et al. 2004). Age can also be a 
significant factor in these analyses; CVD risk and factors contributing to it vary with 
age, and this can further complicate gene analyses and create discordant results. 
Especially transcription factors, such as USF1, which control several other genes, 
can affect many biological pathways simultaneously and perhaps contribute to more 
than one disorder. This hypothesis may be supported by the association of USF1 
SNPs with all-cause mortality in FINRISK (III). Importantly, similar association 
was also noted in the study by Reiner and colleagues in which the rare allele of 
rs2073658 associated with all-cause mortality, just as in FINRISK (III) females, and 
this association was even stronger in non-CVD mortality (Reiner et al. 2007). 
Another complicating factor in our USF1 study, and in other studies of complex 
diseases as well, is the number and nature of the SNPs with functional relevance to 
the disease susceptibility. Many USF1 studies have only examined a few SNPs 
instead of comprehensively studying the USF1 locus for associating variants (Table 
16, Table 17, and Table 18). Furthermore, studies on the expression of downstream 
genes in fat biopsies, have only focused on the initially identified FCHL risk 
variants (Pajukanta et al. 2004; Naukkarinen et al. 2005). These studies have 
indicated differential downstream gene expression dependent of USF1 alleles 
(Pajukanta et al. 2004; Naukkarinen et al. 2005), and have identified an intronic 
sequence which binds nuclear protein (Naukkarinen et al. 2005). Although the USF1 
locus does not seem to harbor any common polymorphisms that alter the amino acid 
sequence of the USF1 protein (Pajukanta et al. 2004; Choquette et al. 2007), SNPs 
in other critical gene regions could also have a functional consequence. Untranslated 
variants can, for instance, affect the transcription level of mRNA, splicing patterns 
and other post-transcriptional modifications of mRNA, or stability or localization of 
mRNA in the cell. Since the chromosomal region of USF1 is characterized by high 
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LD, these functional polymorphisms could reside in the neighboring genes as well 
(Reiner et al. 2007). 
As a ubiquitously expressed transcription factor modulating the expression of 
multiple genes from lipid, inflammation, and glucose metabolism pathways 
(Naukkarinen et al. 2005) (Table 8), USF1 could contribute to the features of the 
traditional CVD risk factors in several ways. Lipid metabolism genes regulated by 
USF1 include apolipoproteins, such as apolipoprotein C-III (APOC3) (Pastier et al. 
2002), apolipoprotein A-V (APOA5) (Nowak et al. 2005), and apolipoprotein A-II 
(APOA2) (Ribeiro et al. 1999), and other important lipid-related genes such as 
acetyl-Coenzyme A carboxylase alpha (ACACA) (Travers et al. 2001), fatty acid 
synthase (FASN) (Wang and Sul 1997; Casado et al. 1999), hormone sensitive lipase 
(LIPE) (Smih et al. 2002),  hepatic lipase (LIPC) (Botma et al. 2001), and 
ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1) (Yang et al. 
2002). Furthermore, USF1 is also involved in the regulation of genes which control 
lipid response to glucose and insulin (Read et al. 1993; Martin et al. 2003a), and 
inflammation related genes such as C-reactive protein (CRP) (Szalai et al. 2005), 
hepcidin (Bayele et al. 2006), beta-2-microglobulin (B2m) (Gobin et al. 2003), and 
C-4-complement gene (Galibert et al. 1997). Suggestive evidence of an association 
between USF1 polymorphisms and inflammation markers, such as plasma CRP and 
IL6 levels, already exists (Reiner et al. 2007).    
Studies on the expression of downstream genes in fat biopsies have already provided 
evidence of the effect of USF1 variation at the tissue level (Pajukanta et al. 2004; 
Naukkarinen et al. 2005). Other studies have demonstrated the involvement of USF1 
in adipocyte lipolysis (Hoffstedt et al. 2005) and in antilipolytic insulin sensitivity 
(Kantartzis et al. 2007). Future functional studies should include several variants 
from the USF1 locus, and should test their functionality in relevant tissues, such as 
coronary arteries.  
Studies with larger sample sizes should also be conducted to confirm our CVD 
results, which were obtained with relatively modest sample sizes. Future studies 
should also test for sex-specific effects and possible interactions with BMI or other 
environmental factors. Finally, upcoming association studies should assess all 
polymorphisms at the USF1 locus and neighboring regions, to effectively evaluate 
the risk increasing or decreasing role of distinct USF1 alleles. 
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6 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
Since the initiation of this study, several publications have described association (or 
sometimes the lack of it) between the upstream transcription factor 1 (USF1) gene 
and dyslipidemias. Some have sought to relate the gene with metabolic syndrome or 
type 2 diabetes, and a few have assessed USF1 variation in relation to cardiovascular 
disease. The aim of this thesis was to examine how USF1 locus contributes to CVD 
risk factors, such as lipid phenotypes and body anthropometrics, at the population 
level, and to atherosclerosis at the vessel wall level. In addition, sudden cardiac 
death and incidence of CVD was analyzed. In the process, we also evaluated how 
whole genome amplification of DNA could improve the amount of samples 
successfully genotyped in genetic studies like ours, and found that a feasible method 
exists. Our study provided information supporting a role for USF1 in the etiology of 
CVD, and paved the way for future USF1-CVD studies. 
Cardiovascular diseases are significant contributors to morbidity and mortality 
worldwide and they have been a subject for intense research. Many, by now 
conventional, risk factors increasing disease susceptibility are known. In the last few 
decades, however, research has increasingly focused on the genetic background of 
these diseases. Despite some success stories, especially concerning rare monogenic 
forms of CVD, many genes underlying CVD susceptibility remain unknown. These 
genes act jointly with other genes and environmental factors, in the etiopathogenesis 
of common, complex forms of CVD. 
During the last few years, several improvements in the field of genetics have 
facilitated the studies of common, complex diseases. Increasing information on 
single nucleotide polymorphisms (SNPs) and their haplotype-tagging properties in 
public databases and improved multiplexing in SNP genotyping platforms have 
enabled several studies with a genome-wide SNP association strategy to emerge. 
Recent publications have also described the nature of previously overlooked 
large-scale variation, such as copy number variation, in the human genome. 
Together, these improvements and new prospects will most likely also lead to many 
discoveries in the field of CVD genetics. 
Identification of genetic risk variants for CVD will not only elucidate the basic 
biology behind the disease, but will also ultimately provide a means for medicine 
and pharmacogenomics to develop better treatment and improved prevention.   
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8 ELECTRONIC DATABASE INFORMATION 
AceView (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/)  
(Thierry-Mieg et al.) 
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) 
ASD, the Alternative Splicing Database  
(http://www.ebi.ac.uk/asd/) (Thanaraj et al. 2004; Stamm et al. 2006) 
BioGRID (http://www.thebiogrid.org/) (Stark et al. 2006) 
Blastn (http://www.ncbi.nlm.nih.gov/BLAST/) (Altschul et al. 1997) 
CleanEx (http://www.cleanex.isb-sib.ch/) 
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) (Sherry et al. 2001) 
Ensembl (http://www.ensembl.org) (Hubbard et al. 2007) 
Entrez Gene  (http://www.ncbi.nlm.nih.gov/entrez) (Maglott et al. 2007) 
Entrez Nucleotide 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=Nucleotide&TabCmd=Limits) 
(Wheeler et al. 2007) 
Entrez PopSet (http://www.ncbi.nlm.nih.gov/sites/entrez?db=Popset) 
Entrez Protein 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=Protein&TabCmd=Limits) 
(Wheeler et al. 2007) 
Finnish National Cardiovascular Disease Register, statistical database 
(http://www.ktl.fi/portal/english/public_health_monitoring___promotion/registe
rs/cardiovascular_diseases/database_overall/) (Mähonen et al. 2000) 
Gene Ontology Database (http://www.geneontology.org/) (Ashburner et al. 2000) 
GeneCards (http://www.genecards.org) (Rebhan et al. 1997) 
GeneLoc (http://bioinfo2.weizmann.ac.il/geneloc) (Rosen et al. 2003) 
GEO, Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)  
(Edgar et al. 2002; Barrett et al. 2007) 
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HapMap (http://www.hapmap.org/) ("The International HapMap Project"  2003) 
HGNC (http://www.gene.ucl.ac.uk/nomenclature/)  
(Wain et al. 2002; Wain et al. 2004) 
HomoloGene (http://www.ncbi.nlm.nih.gov/sites/entrez?db=homologene)  
(Wheeler et al. 2007) 
Human Protein Reference Database (http://www.hprd.org/)  
(Peri et al. 2003; Mishra et al. 2006) 
Integrated DNA Technologies (Oligo Analyzer 3.0) 
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/)  
International Classification of Diseases, Ninth Revision (ICD-9) 
(http://www.cdc.gov/nchs/about/major/dvs/icd9des.htm) 
Oligo Analyzer 3.0 (http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/) 
OMIM (http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM) 
Primer3 (http://frodo.wi.mit.edu/) (Rozen and Skaletsky 2000) 
Repbase Update (http://www.girinst.org/repbase/update/index.html) (Jurka 2000) 
SeattleSNPs (http://pga.gs.washington.edu/)  
(SeattleSNPs, Variation Discovery Resource) 
Sosiaali- ja terveysalan tutkimus- ja kehittämiskeskus (http://www.stakes.fi) 
Tilastokeskus (http://www.tilastokeskus.fi/) (Tilastokeskus 2007b) 
TRANSFAC® Gene Transcription Factor Database (Release 7.0)  
(http://www.gene-regulation.com/pub/databases.html) (Matys et al. 2003) 
UCSC Genome Browser Database (http://genome.ucsc.edu/)  
(Kent et al. 2002; Karolchik et al. 2003) 
UniGene (UniGene) (Pontius et al. 2003) 
UniProtKB/Swiss-Prot (http://www.ebi.uniprot.org)  
(Boeckmann et al. 2003; "The Universal Protein Resource (UniProt)"  2007) 
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